<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearch/1.1/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0' gd:etag='W/&quot;CkcDQXs4fSp7ImA9WhVTEUs.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898</id><updated>2012-02-25T00:54:30.535-08:00</updated><title>Medical Technology Innovation &amp; Investment Journal</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default?redirect=false&amp;v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default?start-index=26&amp;max-results=25&amp;redirect=false&amp;v=2'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>26</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry gd:etag='W/&quot;CkcDQXs_fCp7ImA9WhVTEUs.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-3146744045160643133</id><published>2012-02-24T20:49:00.000-08:00</published><updated>2012-02-25T00:54:30.544-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-25T00:54:30.544-08:00</app:edited><title>SEVEN: Black Tie Event for Life Science Entrepreneurs &amp; Investors</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s1600/SEVEN+logo2012.jpg" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s1600/SEVEN+logo2012.jpg" /&gt;&lt;/a&gt;&lt;/div&gt;
SEVEN
 (Scientific Entrepreneur &amp;amp; Venture Capital Network) Orange County 
is hosting a Life Science Executive Mixer.- &lt;b&gt;Join on Linkedin &lt;a href="http://www.linkedin.com/groups?viewMembers=&amp;amp;gid=2136343&amp;amp;sik=1328685934032"&gt;SEVEN&lt;/a&gt;&lt;/b&gt;&lt;br /&gt;
&amp;nbsp; &lt;br /&gt;
The event is a black tie cocktail event starting at &lt;b&gt;5:30 PM to 9:00PM.&lt;/b&gt;&lt;a href="http://1.bp.blogspot.com/-LLYgNHlyUfU/Tyo3-qicBrI/AAAAAAAAADM/auTx-Qy5P60/s1600/Innovation.jpg" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="237" src="http://1.bp.blogspot.com/-LLYgNHlyUfU/Tyo3-qicBrI/AAAAAAAAADM/auTx-Qy5P60/s320/Innovation.jpg" width="320" /&gt;&lt;/a&gt; &lt;br /&gt;
&lt;b&gt;Date&lt;/b&gt;: 26 April 2012&lt;br /&gt;
&lt;b&gt;Location:&lt;/b&gt; Irvine/Newport Beach&lt;br /&gt;
&lt;b&gt;Registration&lt;/b&gt;: Pl contact Raj at : accessclinicaltrials@gmail.com&lt;br /&gt;
&lt;br /&gt;
Sponsors: Pl contact : Raj at: accessclinicaltrials@gmail.com&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;br /&gt;
&lt;br /&gt;
This
 event will bring the medical device, pharma, biotech and health care IT
 entrepreneurs, executives and the investor community together to boost 
the booming life science industry in Orange County and So Cal.&lt;br /&gt;
&lt;br /&gt;
About &lt;b&gt;200&lt;/b&gt; Life Science executives, investors and start up entrepreneurs are expected to attend.&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-Hga7GMQn34I/TzAJLmQR5TI/AAAAAAAAAGc/JiU1HyVTpxw/s1600/pig+x-ray.jpg" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;b&gt;&lt;img border="0" height="280" src="http://3.bp.blogspot.com/-Hga7GMQn34I/TzAJLmQR5TI/AAAAAAAAAGc/JiU1HyVTpxw/s320/pig+x-ray.jpg" width="320" /&gt;&lt;/b&gt;&lt;/a&gt;&lt;/div&gt;
&lt;span style="font-size: large;"&gt;&lt;b style="color: #444444;"&gt;SEVEN&lt;/b&gt;&lt;/span&gt;
 is screening Medical Device, Biotech, Healthcare IT start up companies 
that would like to have a table top display/presentation (limited to 20 
tabletops only) for an exclusive CEO/Investor Black Tie Event for Life 
Science companies, pl note few spots are left.&amp;nbsp; Pl Email to qualify for 
the event. (Start up with innovative technology, good team, good story) &lt;br /&gt;
&lt;br /&gt;
Pl send your company profile and executive summary to: Raj Nihalani&lt;br /&gt;
E: accessclinicaltrials@gmail.com&lt;br /&gt;
For Registration/attendance pl contact:&amp;nbsp; accessclinicaltrials@gmail.com&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-3146744045160643133?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/3146744045160643133/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=3146744045160643133' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/3146744045160643133?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/3146744045160643133?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/seven-black-tie-event-for-life-science.html' title='SEVEN: Black Tie Event for Life Science Entrepreneurs &amp; Investors'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s72-c/SEVEN+logo2012.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DkANQX05cCp7ImA9WhRaGEs.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-2458477303863504726</id><published>2012-02-21T14:44:00.000-08:00</published><updated>2012-02-21T14:53:10.328-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-21T14:53:10.328-08:00</app:edited><title>Health Care and Medical Device Market Predicted to be over $500B</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
Private investor are jumping in to invest in Medical Device industry as it heats up for a health care boom in Asia by 2015.&amp;nbsp; &lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-HJ41p4pRd1A/T0Qd7e2qBYI/AAAAAAAAALA/iNQ6i-xAa9s/s1600/lap+band.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;img border="0" height="400" src="http://2.bp.blogspot.com/-HJ41p4pRd1A/T0Qd7e2qBYI/AAAAAAAAALA/iNQ6i-xAa9s/s400/lap+band.jpg" width="345" /&gt;&lt;/a&gt;&lt;/div&gt;
The
 increasing incidence of chronic diseases such as Obesity,&amp;nbsp; diabetes, 
cardiovascular disease, chronic wounds, immobility, pulmonary and 
vascular diseases is enhancing the need for patient care in hospitals, 
homes and other care facilities, thereby contributing to the demand for 
medical devices and diagnostics that are capable of enhancing the 
overall quality of life. The US leads the high-technology medical 
devices market, but faces fierce competition from emerging economies. 
Despite being way behind the US in terms of expertise or innovation, 
these countries compete on basis of production of low cost medical 
devices. Demand for medical devices in developing countries, especially 
China and India, is expected to grow at a faster rate than developed 
countries owing to factors such as rising disposable incomes, increase 
in patient population, growing waist lines, obesity on the rise and both
 India and China face an epidemic of diabetes and obeisty. Australia UK ,
 US, Canada and Mexico are already declared an Obesity epidemic. The 
obesity device market will be the biggest in the healthcare sector.&lt;br /&gt;
Asia is seeing increasing healthcare awareness, improvements in 
healthcare infrastructure and increase in healthcare spending . In 
majority of the Asian, Latin America and the Middle East countries, 
government efforts are focused on improving healthcare services and 
infrastructure facilities, which is expected to fuel the demand for 
medical equipment in the next 3 years.&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://4.bp.blogspot.com/-xTGn3QlDs_g/T0QdffKQ1XI/AAAAAAAAAK4/1aHFFTRkQV8/s1600/spine.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="320" src="http://4.bp.blogspot.com/-xTGn3QlDs_g/T0QdffKQ1XI/AAAAAAAAAK4/1aHFFTRkQV8/s320/spine.jpg" width="264" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
The medical device industry has not been totally insulated from the 
adverse economic conditions, as evident by the decline in admissions 
across healthcare facilities and hospitals. Owing to the high levels of 
unemployment, elective, orthopedic, and cosmetic procedures witnessed a 
significant decline, thereby affecting profitability of hospitals. 
Additionally, rising capital costs, declining patient volumes, and 
unfavorable reimbursement scenario affected revenue generation. With 
most surgical systems and equipment being capital heavy investments, 
tight liquidity, lack of credit availability, capital shortages, and 
high borrowing rates, triggered by the recession, forced hospitals and 
healthcare facilities to reduce capital expenditures on new equipment. 
Though developed countries such as North America, Japan and Western and 
Northern Europe witnessed subdued spending on healthcare services, level
 of healthcare expenditure in developing markets continued to increase 
thereby fuelling the demand for medical technologies, products and 
services. However, mounting healthcare expenditure presents a 
considerable challenge for most countries, particularly in developed 
countries that are already grappling with the volatile economic 
environment.&lt;br /&gt;
India and china face a problem of metabolic disease. 
Which is a mix of hypertention, heart disease and diabetes. The smokers 
in the region have increased the incidence of tobacco related problems.&lt;br /&gt;
Coronary stent shown below is one medical device that is implanted every 20 seconds in Asia. &lt;br /&gt;
&lt;a href="http://2.bp.blogspot.com/-ZSCN2EqLK2o/T0QS010qkzI/AAAAAAAAAKo/0KBj_bk3Zzw/s1600/Stend+image.jpg" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://2.bp.blogspot.com/-ZSCN2EqLK2o/T0QS010qkzI/AAAAAAAAAKo/0KBj_bk3Zzw/s1600/Stend+image.jpg" /&gt;&lt;/a&gt;There is a increased demand in consumables in the medical device sector. Implantables like the lap band will grow in Asia.&lt;br /&gt;
Technologies in orthopedics and spine are in great demand. Larger companies cannot compete with small and nimble manufacturers.&lt;br /&gt;
Spine
 surgery is reverting to posterior open repairs due to slower adoption 
of minimally invasive surgery. The outcomes show little difference 
between the traditional posterior fixation and minimally invasive 
surgery. It will take a decade for new technologies to be adopted.&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-8bdvY0jo-bQ/T0QeJWiCCbI/AAAAAAAAALI/Lg_IpS9SdDo/s1600/med+device.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;img border="0" height="320" src="http://3.bp.blogspot.com/-8bdvY0jo-bQ/T0QeJWiCCbI/AAAAAAAAALI/Lg_IpS9SdDo/s320/med+device.jpg" width="296" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
Increase
 number of private investors are jumping into the space because the 
institutional investors have not raised new money to invest in early 
stage technologies.&lt;br /&gt;
&amp;nbsp;Private investors did not have this opportunity until recently.&lt;br /&gt;
Private and angel investors understand its a high risk high gain opportunity, accredited investors can take advantage and invest in companies in the seed stage and series A. After Series A&amp;nbsp; the institutional investors and venture capitalist jump in. Many of the private investors have potential to gain if the company exits in 4-5 years, which can be by virtue of M&amp;amp;A or IPO. &lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-2458477303863504726?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/2458477303863504726/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=2458477303863504726' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2458477303863504726?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2458477303863504726?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/health-care-and-medical-device-market.html' title='Health Care and Medical Device Market Predicted to be over $500B'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-HJ41p4pRd1A/T0Qd7e2qBYI/AAAAAAAAALA/iNQ6i-xAa9s/s72-c/lap+band.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;A0QGR306eip7ImA9WhRaEko.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-1261088899967280537</id><published>2012-02-13T18:31:00.000-08:00</published><updated>2012-02-14T20:15:26.312-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-14T20:15:26.312-08:00</app:edited><title>Med Device , Pharma, Biotech &amp; Health Care IT Start up and Executives Mixer, Newport Beach. California</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div style="color: #eeeeee;"&gt;
&lt;b&gt;&lt;span style="font-size: large;"&gt;SEVEN (Scientific Entrepreneur &amp;amp; Venture Capital Network) &lt;/span&gt;Orange 
County is hosting a Life Science Executive Mixer.- Join on Linkedin.&lt;a href="http://www.linkedin.com/groups?viewMembers=&amp;amp;gid=2136343&amp;amp;sik=1328685934032"&gt;SEVEN&lt;/a&gt;&lt;/b&gt;&lt;/div&gt;
&amp;nbsp; &lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://1.bp.blogspot.com/--bdVMPgkXDI/TznG4NOoX0I/AAAAAAAAAIU/wlrsegHE-WA/s1600/SEVEN+meeting+april+26,+2012.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="320" src="http://1.bp.blogspot.com/--bdVMPgkXDI/TznG4NOoX0I/AAAAAAAAAIU/wlrsegHE-WA/s320/SEVEN+meeting+april+26,+2012.jpg" width="315" /&gt;&lt;/a&gt;&lt;/div&gt;
The event is a black tie cocktail event starting at 5:30 PM to 9:00PM.&lt;br /&gt;
Date: 26 April 2012&lt;br /&gt;
Location: Irvine/Newport Beach&lt;br /&gt;
Sponsors: Pl contact : &lt;b&gt;Raj &lt;/b&gt;at: &lt;b&gt;accessclinicaltrials@gmail.com&lt;/b&gt;&lt;br /&gt;
or&lt;br /&gt;
&lt;b&gt;Raj@trialmed.com&lt;/b&gt;&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;This event will bring the medical device, pharma, biotech and health 
care IT entrepreneurs, executives and the investor community together to
 boost the booming life science industry in Orange County and So Cal.&lt;/b&gt;&lt;br /&gt;
About &lt;b&gt;200&lt;/b&gt; Life Science executives, investors and start up entrepreneurs are expected to attend.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-Hga7GMQn34I/TzAJLmQR5TI/AAAAAAAAAGc/JiU1HyVTpxw/s1600/pig+x-ray.jpg" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/a&gt;&lt;/div&gt;
&lt;span style="font-size: medium;"&gt;&lt;b style="color: #444444;"&gt;SEVEN&lt;/b&gt;&lt;/span&gt;
 is screening Medical Device, Biotech, Healthcare IT start up companies 
that would like to have a table top display/presentation (limited to 20 
tabletops only) for an exclusive CEO/Investor Black Tie Event for Life 
Science companies, pl note few spots are left.&amp;nbsp; Pl Email to qualify for 
the event. (Start up with innovative technology, good team, good story) &lt;br /&gt;
&lt;br /&gt;
Pl send your company profile and executive summary to: Raj Nihalani&lt;br /&gt;
E: accessclinicaltrials@gmail.com&lt;br /&gt;
For Registration/attendance pl contact:&amp;nbsp; accessclinicaltrials@gmail.com&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-1261088899967280537?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/1261088899967280537/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=1261088899967280537' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1261088899967280537?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1261088899967280537?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/med-device-pharma-biotech-health-care.html' title='Med Device , Pharma, Biotech &amp; Health Care IT Start up and Executives Mixer, Newport Beach. California'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/--bdVMPgkXDI/TznG4NOoX0I/AAAAAAAAAIU/wlrsegHE-WA/s72-c/SEVEN+meeting+april+26,+2012.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DUcASXg_fCp7ImA9WhRaEUw.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-5094087925132056975</id><published>2012-02-12T23:07:00.000-08:00</published><updated>2012-02-12T23:10:48.644-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-12T23:10:48.644-08:00</app:edited><title>Key to Medical Technology Boom</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;a href="http://1.bp.blogspot.com/-d7LyrXfsQw0/Tziy04j9q2I/AAAAAAAAAHE/hNavQZR3jjU/s1600/Key+medtech.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="320" src="http://1.bp.blogspot.com/-d7LyrXfsQw0/Tziy04j9q2I/AAAAAAAAAHE/hNavQZR3jjU/s320/Key+medtech.jpg" width="287" /&gt;&lt;/a&gt;&lt;span style="font-size: x-large;"&gt;C&lt;span style="font-size: small;"&gt;ontinued&lt;/span&gt;&lt;/span&gt; years of strong and steady growth, the medical technology 
industry is facing a wave of pressure that is forcing companies in the 
industry to re-examine the fundamentals of how they compete. The 
traditional medical technology model that is purely focused on product 
innovation will not be a the only play in the future. Instead, 
high performance in the medical technology industry will stem from the 
ability to develop cost-effective solutions driven by the change in 
buyers that deliver demonstrable improvements in health outcomes. &lt;br /&gt;
Example; &lt;b&gt;Spinofix, Inc&lt;/b&gt; is a Irvine, CA based spine technology, is working on a low cost option in the posterior spine fixation technology, it has a unique cross connector system that replaces the spinous process that is dissected out during the spine laminectomy procedure to decompress the spinal cord and the nerves. The technology is fresh, low cost and can impact health outcomes. The company is poised to play a big role in the US and OUS (Outside US) spine market.&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-kojIqi93Lug/Tzi17ahU5jI/AAAAAAAAAHM/JDYfNr7oyME/s1600/financial.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;img border="0" height="135" src="http://3.bp.blogspot.com/-kojIqi93Lug/Tzi17ahU5jI/AAAAAAAAAHM/JDYfNr7oyME/s400/financial.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
Undoubtedly, the changes medical technology companies make will be the key contributor to the med tech boom worldwide and the booming M&amp;amp;A market;&lt;br /&gt;
Medical technology companies however, will need to 
transform their business models to meet the changing demands of health 
care systems globally. They must carefully choose where to focus their 
energies both in terms of product and markets. Medical technology 
companies then must align the right capabilities, innovation models and 
partnerships that will unlock future growth in these market areas. As a result there is an increase in M&amp;amp;A activity in the medical 
device sector. Companies are more cash positive than ever, so buying 
capacity has increased at a decent valuations. US acquirers have to 
compete with international pharma companies for acquisition of domestic 
companies.&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-5094087925132056975?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/5094087925132056975/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=5094087925132056975' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5094087925132056975?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5094087925132056975?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/c-ontinued-years-of-strong-and-steady.html' title='Key to Medical Technology Boom'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-d7LyrXfsQw0/Tziy04j9q2I/AAAAAAAAAHE/hNavQZR3jjU/s72-c/Key+medtech.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;D0QGQ3Y9eSp7ImA9WhRaEUU.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8451812465087044559</id><published>2012-02-06T09:35:00.000-08:00</published><updated>2012-02-13T18:08:42.861-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-13T18:08:42.861-08:00</app:edited><title>SEVEN: Scientific Entrepreneur &amp; Venture Capital Network  Orange County</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s1600/SEVEN+logo2012.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s1600/SEVEN+logo2012.jpg" /&gt;&lt;/a&gt;&lt;/div&gt;
SEVEN (Scientific Entrepreneur &amp;amp; Venture Capital Network) Orange County is hosting a Life Science Executive Mixer.- Join on Linkedin.&lt;a href="http://www.linkedin.com/groups?viewMembers=&amp;amp;gid=2136343&amp;amp;sik=1328685934032"&gt;SEVEN&lt;/a&gt;&lt;br /&gt;
&amp;nbsp; &lt;br /&gt;
The event is a black tie cocktail event starting at 5:30 PM to 9:00PM.&lt;br /&gt;
Date: 26 April 2012&lt;br /&gt;
Location: Irvine/Newport Beach&lt;br /&gt;
Sponsors: Pl contact : Raj at: accessclinicaltrials@gmail.com&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This event will bring the medical device, pharma, biotech and health care IT entrepreneurs, executives and the investor community together to boost the booming life science industry in Orange County and So Cal.&lt;br /&gt;
About &lt;b&gt;200&lt;/b&gt; Life Science executives, investors and start up entrepreneurs are expected to attend.&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-Hga7GMQn34I/TzAJLmQR5TI/AAAAAAAAAGc/JiU1HyVTpxw/s1600/pig+x-ray.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;b&gt;&lt;img border="0" height="280" src="http://3.bp.blogspot.com/-Hga7GMQn34I/TzAJLmQR5TI/AAAAAAAAAGc/JiU1HyVTpxw/s320/pig+x-ray.jpg" width="320" /&gt;&lt;/b&gt;&lt;/a&gt;&lt;/div&gt;
&lt;span style="font-size: large;"&gt;&lt;b style="color: #444444;"&gt;SEVEN&lt;/b&gt;&lt;/span&gt; is screening Medical Device, Biotech, Healthcare IT start up companies that would like to have a table top display/presentation (limited to 20 tabletops only) for an exclusive CEO/Investor Black Tie Event for Life Science companies, pl note few spots are left.&amp;nbsp; Pl Email to qualify for the event. (Start up with innovative technology, good team, good story) &lt;br /&gt;
&lt;br /&gt;
Pl send your company profile and executive summary to: Raj Nihalani&lt;br /&gt;
E: accessclinicaltrials@gmail.com&lt;br /&gt;
For Registration/attendance pl contact:&amp;nbsp; accessclinicaltrials@gmail.com&lt;br /&gt;
There is opportunity to sponsor the event. pl call: 714-658-3039 &lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://1.bp.blogspot.com/-LLYgNHlyUfU/Tyo3-qicBrI/AAAAAAAAADM/auTx-Qy5P60/s1600/Innovation.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="297" src="http://1.bp.blogspot.com/-LLYgNHlyUfU/Tyo3-qicBrI/AAAAAAAAADM/auTx-Qy5P60/s400/Innovation.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8451812465087044559?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8451812465087044559/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8451812465087044559' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8451812465087044559?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8451812465087044559?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/seven-scientific-entrepreneur-venture.html' title='SEVEN: Scientific Entrepreneur &amp; Venture Capital Network  Orange County'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-rukVCLXf2aQ/TzIkYx3E6RI/AAAAAAAAAGs/KCs2TZ-hmkM/s72-c/SEVEN+logo2012.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;C0MDQnkyfyp7ImA9WhRbFUU.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-4395414762549792215</id><published>2012-02-04T16:58:00.000-08:00</published><updated>2012-02-06T18:24:33.797-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-06T18:24:33.797-08:00</app:edited><title>China Life Science Innovation Occuring Via Investments in Early Stage Companies &amp; M&amp;A</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: left;"&gt;
&lt;a href="http://2.bp.blogspot.com/-gbHqDz8GTDw/Ty3MLtMeEzI/AAAAAAAAAFE/Mk4g7SgcQt0/s1600/Chinese+M%2526A+in+Life+sciences.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="200" src="http://2.bp.blogspot.com/-gbHqDz8GTDw/Ty3MLtMeEzI/AAAAAAAAAFE/Mk4g7SgcQt0/s200/Chinese+M%2526A+in+Life+sciences.jpg" width="84" /&gt;&lt;/a&gt; &lt;span style="font-size: large;"&gt;&lt;b&gt;China &lt;/b&gt;&lt;/span&gt;investing in obesity, diabetes, orthopedics, cardiovasular and generic pharmaceutical and medical device technologies. More Chinese VCs are taking advantage of US based startups in the medical device &amp;amp; pharmacutical startups.&lt;a href="http://2.bp.blogspot.com/-hIVKHZixnfY/Ty3PLbi9R0I/AAAAAAAAAFs/fWP93waAlcI/s1600/chinese+obesity.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;img border="0" height="200" src="http://2.bp.blogspot.com/-hIVKHZixnfY/Ty3PLbi9R0I/AAAAAAAAAFs/fWP93waAlcI/s200/chinese+obesity.jpg" width="133" /&gt;&lt;/a&gt;&lt;/div&gt;
US based VCs are now raising new funds, in the past 3 years they have not raised funds (2009-2011) and are unable to invest in companies that are early stage. China is taking full advantage of novel medtech companies focused on chronic diseases like cardiovascular, diabetes, and newer unmet needs like obesity.&lt;br /&gt;
Even countries like India, Taiwan are exploring the opportunity to fund US based start ups. Taiwan just created a Supra Incubation Project to promote life sciences. This effort is an indicator that the life science sector is going to boom in Asia and the effects will trickle to the west and result in a worldwide boom in the life science industry.&lt;br /&gt;
&amp;nbsp;  &lt;br /&gt;
&lt;div class="MsoNormal"&gt;
The potential for China’s medical device, pharmaceutical industry stands out among emerging market peers as pharmaceutical companies contrast the fast growing China market with slightly slow growth in Europe and North America. Unique among the BRIC markets, the Chinese govt announced a US$124 Billion in healthcare stimulus to offer health insurance to over 90% of the Chinese population by 2011, fueling China’s pharmaceutical and medical device market to become the 3&lt;sup&gt;rd&lt;/sup&gt; largest in the world by 2012.&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
China has some unmet clinical needs. For example, China represents nearly 50% of liver cancer cases in the world. &amp;nbsp;China’s one child policy has led to children who are now overweight and fighting obesity. The new prosperity along with the western diet is making the children and adults obese. China is seeing the fastest obesity rates. With obesity come problems like diabetes, spine and joint problems. India and China will be the capital of diabetes in the world.&amp;nbsp;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-YKXHa5Cnv9E/Ty3MFgzxe-I/AAAAAAAAAE8/BLjVMxp4L4g/s1600/chinese+M%2526A+intro.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="233" src="http://2.bp.blogspot.com/-YKXHa5Cnv9E/Ty3MFgzxe-I/AAAAAAAAAE8/BLjVMxp4L4g/s400/chinese+M%2526A+intro.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="color: #cfe2f3;"&gt;
&lt;span style="font-size: small;"&gt;&lt;b&gt;China lacks: Innovation&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
The infrastructure is starting to get in place, but to start innovating will take many years. US is already ahead due to investments in the education and R&amp;amp;D infrastructure and experience. However, China can invest and buy innovative companies and compete with US based companies.&amp;nbsp;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-moZcHfRq1Dc/Ty3PzAS_0WI/AAAAAAAAAF0/d31uNg0Jmpc/s1600/chinese+M&amp;amp;A+pharma3.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="340" src="http://2.bp.blogspot.com/-moZcHfRq1Dc/Ty3PzAS_0WI/AAAAAAAAAF0/d31uNg0Jmpc/s640/chinese+M&amp;amp;A+pharma3.jpg" width="640" /&gt;&lt;/a&gt;&lt;/div&gt;
&amp;nbsp; &lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-zTRwdaWQ3Bs/Ty3QZ5-8qXI/AAAAAAAAAGM/BeruogIU-Yc/s1600/Chinese+M&amp;amp;A+refreces.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="104" src="http://2.bp.blogspot.com/-zTRwdaWQ3Bs/Ty3QZ5-8qXI/AAAAAAAAAGM/BeruogIU-Yc/s640/Chinese+M&amp;amp;A+refreces.jpg" width="640" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-hd9cKf6r1no/Ty3QGAwS2xI/AAAAAAAAAGE/KLcQdJsHW2M/s1600/Chinese+M&amp;amp;A+2.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="640" src="http://3.bp.blogspot.com/-hd9cKf6r1no/Ty3QGAwS2xI/AAAAAAAAAGE/KLcQdJsHW2M/s640/Chinese+M&amp;amp;A+2.jpg" width="608" /&gt;&lt;/a&gt;&lt;/div&gt;
Life Science industry poised for a boom in China and the other BRIC countries. US investors may lose the opportunity to invest in early stage companies in the US. Chinese investors may invest in these companies all the way to exit or IPO (which could be listed in the US or China). Recently, Boston based GI Dynamics went public on the Australian stock exchange. The world is indeed flat. Life Science Innovators have more choices now than ever.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-4395414762549792215?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/4395414762549792215/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=4395414762549792215' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/4395414762549792215?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/4395414762549792215?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/china-life-science-innovation-occuring.html' title='China Life Science Innovation Occuring Via Investments in Early Stage Companies &amp; M&amp;A'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-gbHqDz8GTDw/Ty3MLtMeEzI/AAAAAAAAAFE/Mk4g7SgcQt0/s72-c/Chinese+M%2526A+in+Life+sciences.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;AkEARH4_fCp7ImA9WhRbE0Q.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-5755976063477998874</id><published>2012-02-04T15:37:00.000-08:00</published><updated>2012-02-04T15:37:25.044-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-04T15:37:25.044-08:00</app:edited><title>Top Sector for Innovation: Life Sciences</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;br /&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-_sxPW_1R_i0/TyzwtAvMZ4I/AAAAAAAAAEs/Hvu5N0EMhS4/s1600/innovation+california.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="296" src="http://3.bp.blogspot.com/-_sxPW_1R_i0/TyzwtAvMZ4I/AAAAAAAAAEs/Hvu5N0EMhS4/s640/innovation+california.jpg" width="640" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
Lost in the midst of the seemingly endless headlines of Facebook&amp;nbsp; IPO and the disasters of the recession, is
the fact that today is a time of great innovation with medical products,
technology, and entertainment that would have been simply unimaginable in any
other time. And the innovations of recent decades are poised to continue helping
to reshape our lives to be more productive, healthy, and entertaining.&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
Every day it seems, headlines remind us that the
astronomical costs of health care are snowballing. But however daunting this
environment may be, Investors&amp;nbsp; believe it also provides tremendous opportunities, thanks
to a steady stream of new discoveries and groundbreaking practices. Innovation
in biotech, medtech, and health care IT [information technology] that can
improve the delivery and quality of health care, as well as curtail overall
expenses. Eg: Spinofix, Inc is working on next generation spine technology. Onciomed, Inc is another technology that is addressing the $200 Billion obesity, weight loss and diabetes market.&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
The scientific community continues to make exciting strides
in understanding the human genome groundbreaking research that may change our
comprehension of human biology and the future course of medicine. Simply put,
we’re going through a biological revolution the likes of which we haven’t seen
in a generation. Nanotechnology is already playing a role in cosmetics, and beauty creams, lotions. The entire biotechnology sector is going to lead to better drug discovery and,
ultimately, much more personalized medicine. The treatment paradigms could
shift to pinpoint each patient, as opposed to a subset of patients with a
shared illness. In other words, the treatment could be unique and special to
each patient.&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://3.bp.blogspot.com/-P_sJ45063p8/Ty3AmtIgQ8I/AAAAAAAAAE0/vAVVMAX_Yeo/s1600/pharma+6.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="234" src="http://3.bp.blogspot.com/-P_sJ45063p8/Ty3AmtIgQ8I/AAAAAAAAAE0/vAVVMAX_Yeo/s320/pharma+6.jpg" width="320" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
As life sciences takes a unique turn in this decade, this sector of medical devices, biotech, health care IT has the potential to lead the next economic boom. &lt;br /&gt;
&lt;br /&gt;
Join &lt;span style="color: yellow;"&gt;SCIENTIFIC ENTREPRENEUR &amp;amp; VENTURE CAPITAL NETWORK&lt;/span&gt;&amp;nbsp; on LINKEDIN&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-5755976063477998874?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/5755976063477998874/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=5755976063477998874' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5755976063477998874?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5755976063477998874?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/top-sector-for-innovation-life-sciences.html' title='Top Sector for Innovation: Life Sciences'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/-_sxPW_1R_i0/TyzwtAvMZ4I/AAAAAAAAAEs/Hvu5N0EMhS4/s72-c/innovation+california.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DEcFQ3c6eSp7ImA9WhRbE08.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8998524894838868431</id><published>2012-02-03T19:26:00.000-08:00</published><updated>2012-02-03T19:26:52.911-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-03T19:26:52.911-08:00</app:edited><title>Best Sector to Invest: Medical Device S&amp;P benchmark with S&amp;P 500</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
Medical Device Industry also known as the healthcare equipment and diagnostic companies have shown tremendous resistance to the recession. Many venture capitalist have not raised funds since 2008 and are not investing in the early stage companies, this give the opportunity to private investors to jump in. This opportunity did not exist earlier. In 2012, VCs have started raising new funds to invest in life science companies. The funds will take 12-15 months to raise, this gives the private investors additional time and opportunity to invest in innovative technologies.&lt;br /&gt;
The demand of medical product is increasing worldwide. It appears 2015 will see a medical and life sciences boom. &lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-UFC3TussyLo/TyyeArex5ZI/AAAAAAAAADU/CzsExLaWATw/s1600/S&amp;amp;P+500+and+Medical+Device+S&amp;amp;P.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="218" src="http://2.bp.blogspot.com/-UFC3TussyLo/TyyeArex5ZI/AAAAAAAAADU/CzsExLaWATw/s400/S&amp;amp;P+500+and+Medical+Device+S&amp;amp;P.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://4.bp.blogspot.com/-gc3mM6lZSYI/Tyyh3Fh7wbI/AAAAAAAAAD0/DaY-P5ovRSQ/s1600/S&amp;amp;P+year+to+date.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="218" src="http://4.bp.blogspot.com/-gc3mM6lZSYI/Tyyh3Fh7wbI/AAAAAAAAAD0/DaY-P5ovRSQ/s400/S&amp;amp;P+year+to+date.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://1.bp.blogspot.com/-3ai2GOXqywU/TyyiBn5kL9I/AAAAAAAAAEE/_P8rQgjTd2Q/s1600/S&amp;amp;P+Nasqaq++year+to+date.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="218" src="http://1.bp.blogspot.com/-3ai2GOXqywU/TyyiBn5kL9I/AAAAAAAAAEE/_P8rQgjTd2Q/s400/S&amp;amp;P+Nasqaq++year+to+date.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;a href="http://2.bp.blogspot.com/-Pu6a7bOAFjY/TyyiNBkZygI/AAAAAAAAAEU/_NRbF-iiGss/s1600/S&amp;amp;P+Russels.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="218" src="http://2.bp.blogspot.com/-Pu6a7bOAFjY/TyyiNBkZygI/AAAAAAAAAEU/_NRbF-iiGss/s400/S&amp;amp;P+Russels.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;
&lt;/div&gt;
&lt;br /&gt;
The above charts speak for itself.&lt;br /&gt;
&lt;span id="ctl00_ctl00_MainContent_A2_ctl00_contentService12"&gt;Growth and value investors can find investing in medical equipment companies lucrative. &lt;/span&gt;&lt;span id="ctl00_ctl00_MainContent_A2_ctl00_contentService12"&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span id="ctl00_ctl00_MainContent_A2_ctl00_contentService12"&gt;&lt;span&gt;With the &lt;/span&gt;&lt;/span&gt;&lt;span id="ctl00_ctl00_MainContent_A2_ctl00_contentService12"&gt;&lt;em&gt;Aging Population &lt;/em&gt;many
 countries are experiencing an aging population. This growing segment of
 the population is a positive influence on the future performance of 
medical equipment companies. Essentially, the rising tide of an aging 
population helps all the medical equipment companies grow.&lt;/span&gt;&lt;br /&gt;
&lt;span id="ctl00_ctl00_MainContent_A2_ctl00_contentService12"&gt;&lt;span&gt;The 
medical equipment sector is well positioned to take advantage of a 
growing demand for healthcare if the elderly become a larger percentage 
of the overall population. Moreover, innovations offer ways to improve 
the lives and welfare of everyone. The best time to buy depends on the 
type of investor you are. Growth investors can take advantage of the 
rapid innovation that many companies can accomplish. &lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;div style="background-color: white; border: medium none; color: black; overflow: hidden; text-align: left; text-decoration: none;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style="background-color: white; border: medium none; color: black; overflow: hidden; text-align: left; text-decoration: none;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8998524894838868431?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8998524894838868431/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8998524894838868431' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8998524894838868431?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8998524894838868431?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/best-sector-to-invest-medical-device-s.html' title='Best Sector to Invest: Medical Device S&amp;P benchmark with S&amp;P 500'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-UFC3TussyLo/TyyeArex5ZI/AAAAAAAAADU/CzsExLaWATw/s72-c/S&amp;P+500+and+Medical+Device+S&amp;P.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DEQFQX0zfip7ImA9WhRbE0w.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-2531796946125549393</id><published>2012-02-03T16:44:00.001-08:00</published><updated>2012-02-03T16:45:10.386-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-02-03T16:45:10.386-08:00</app:edited><title>Warren Buffet Rules Application to Med-Tech Startup</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;b&gt;No. 1: &amp;nbsp;REINVEST YOUR PROFITS&lt;/b&gt; – When you first make 
money, you may be tempted to spend it. &amp;nbsp;Don’t. &amp;nbsp;Instead, reinvest the 
profits. &amp;nbsp;Buffett learned this early on. In high school, he and a pal 
bought a pinball machine to put in a barbershop. With the money they 
earned, they bought more machines until they had eight in different 
shops. When the friends sold the venture, Buffett used the proceeds to 
buy stocks and to start another business.&lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;Many medical
 and life science technologies are R&amp;amp;D based. So if you sell your 
company, re invest in a new venture. Don't blow it!&lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 2: &amp;nbsp;BE WILLING TO BE DIFFERENT&lt;/b&gt; -&amp;nbsp;Don’t base your
 decisions upon what everyone is saying or doing. When Buffett began 
managing money in 1956 with $100,000 cobbled together from a handful of 
investors, he was dubbed an oddball. He worked in Omaha, not on Wall 
Street, and he refused to tell his partners where he was putting their 
money. People predicted that he’d fall, but when he closed his 
partnership 14 years later, it was worth more than $100 million.&lt;br /&gt;
&lt;br /&gt;
You
 will come across investors and companies looking at your technology and
 might say, " your technology is not a fit or does not attract us" you 
pursue your technology,&amp;nbsp; make sure you are realistic about the growth 
and outcome of the company. If one investor rejects it, another will see
 value, nobody knows! better Eg; Facebook.&amp;nbsp; &lt;br /&gt;
&lt;br /&gt;
&lt;img alt="" src="data:image/jpeg;base64,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" /&gt;&lt;br /&gt;
&lt;b&gt;No. 3: &amp;nbsp;NEVER SUCK YOUR THUMB&lt;/b&gt; -&amp;nbsp;&lt;b&gt;Gather in advance 
any information you need to make a decision, and ask a friend or 
relative to make sure that you stick to a deadline. Buffett prides 
himself on swiftly making up his mind and acting on it. He calls any 
unnecessary sitting and thinking “thumb-sucking.”&lt;/b&gt;&lt;br /&gt;
&lt;br /&gt;
Sometimes
 in the medtech sector the outcomes depend on the user too. Have they 
followed your instruction to use the medical device or product, was the 
patient qualified to get your treatment, did you provide adequate 
training...all this consumes time, Don't make hasty decisions,&amp;nbsp; take a 
break and get back at it! harder and more tactfully, this time with a 
new strategy. &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 4: &amp;nbsp;SPELL OUT THE DEAL BEFORE YOU START&lt;/b&gt; -&amp;nbsp;Your 
bargaining leverage is always greatest before you begin a job – that’s 
when you have something to offer that the other party wants. Buffett 
learned&lt;br /&gt;
&lt;br /&gt;
this lesson the hard way as a kid, when his grandfather Earnest 
hired him and a friend to dig out the family grocery store after a 
blizzard. The boys spent five hours shoveling until they could barely 
straighten their frozen hands. Afterward, his grandfather gave the pair 
less that 90 cents to split.&lt;br /&gt;
&lt;br /&gt;
As a life science 
entrepreneur, your bargaining starts with the investors and ends with 
the acquirer. So be on your toes! learn ..learn ...learn &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 5: &amp;nbsp;WATCH SMALL EXPENSES&lt;/b&gt; -&amp;nbsp;Buffett invests in 
business run by managers who obsess over the tiniest costs. He once 
acquired a company whose owner counted the sheets in rolls of 500-sheet 
toilet paper to see if he was being cheated (he was). He also admired a 
friend who painted only the side of his office building that faced the 
road.&lt;br /&gt;
&lt;br /&gt;
Many startups make a mistake of spending. I think after the recent recession, lessons have been learned. &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 6: &amp;nbsp;LIMIT WHAT YOU BORROW&lt;/b&gt; -&amp;nbsp;Buffett has never 
borrowed a significant amount – not to invest, not for a mortgage. He 
has gotten many heartrending letters from people who thought their 
borrowing was manageable but became overwhelmed by debt. His advice: 
Negotiate with creditors to pay what you can. Then, when you’re 
debt-free, work on saving some money that you can invest.&lt;br /&gt;
&lt;br /&gt;
In a life science company, debt free is better. &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 7: &amp;nbsp;BE PERSISTENT&lt;/b&gt; -&amp;nbsp;With tenacity and ingenuity,
 you can win against a more established competitor. Buffett acquired the
 Nebraska Furniture Mart in 1983 because he liked the way its founder, 
Rose Blumkin, did business. A Russian immigrant, she built the mart from
 a pawnshop into the largest furniture store in North America. Her 
strategy was to undersell the big shots, and she was a merciless 
negotiator.&lt;br /&gt;
&lt;br /&gt;
#1 Rule of the game. Be Patient! Persistent &amp;amp; Passionate: Everything takes time.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 8: &amp;nbsp;KNOW WHEN TO QUIT&lt;/b&gt; -&amp;nbsp;Once, when Buffett was a
 teen, he went to the racetrack. He bet on a race and lost. To recoup 
his funds, he bet on another race. He lost again, leaving him with close
 to nothing. He felt sick – he had squandered nearly a week’s earnings. 
Buffett never repeated that mistake.&lt;br /&gt;
&lt;br /&gt;
I think Buffent 
meant "don't gamble". If you have the right recipe, give it your best 
shot, in life sciences, the patient outcomes will direct you to quit or 
stay in the game, don't quit too early. You might be able to change the 
game with small modifications to your technology. &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 9: &amp;nbsp;ASSESS THE RISKS&lt;/b&gt; -&amp;nbsp;In 1995, the employer of 
Buffett’s son, Howie, was accused by the FBI of price-fixing. Buffett 
advised Howie to imagine the worst- and best-case scenarios if he stayed
 with the company. His son quickly realized the risks of staying far 
outweighed any potential gains, and he quit the next day.&lt;br /&gt;
&lt;br /&gt;
As
 a life science entrepreneur, you know better the risk and benefits of 
the product and the risk and benefit of sticking around and building 
value.&amp;nbsp; &lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;No. 10: &amp;nbsp;KNOW WHAT SUCCESS REALLY MEANS&lt;/b&gt; -&amp;nbsp;Despite 
his wealth, Buffett does not measure success by dollars. In 2006, he 
pledged to give away almost his entire fortune to charities, primarily 
the Bill and Melinda Gates Foundation. He’s adamant about not funding 
monuments to himself – no Warren Buffett buildings or halls. “When you 
get to my age, you’ll measure your success in life by how many of the 
people you want to have love you actually do love you. That’s the 
ultimate test of how you lived your life.”&lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;Success is not about winning or losing, its how you played the game.!&lt;br /&gt;
&lt;br /&gt;
Medical
 technology is booming world wide, sometimes funding the company is 
challenging, cast a wider net, you will prevail! have faith, believe in 
yourself, and believe in the technology you created or represent, be 
real with your team, keep them engaged and treat them like family. Once 
the life science boom occurs in a couple of years, the valuations of the
 company will be all time high and all parties involved with the company
 will be rewarded.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-2531796946125549393?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/2531796946125549393/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=2531796946125549393' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2531796946125549393?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2531796946125549393?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/02/warren-buffet-rules-application-to-med.html' title='Warren Buffet Rules Application to Med-Tech Startup'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DEEERHo6cCp7ImA9WhRUEko.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-6182471556080035310</id><published>2012-01-22T15:48:00.000-08:00</published><updated>2012-01-22T15:56:45.418-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-22T15:56:45.418-08:00</app:edited><title>5 Ways of Creating High Valuations for Your Life Science Company</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;
&lt;br /&gt;
&lt;div class="MsoNormal" style="color: yellow;"&gt;
&lt;b&gt;&lt;span style="font-size: 18pt;"&gt;5 Ways of Creating High Valuations for Your
Life Science Company&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;ol start="1" style="color: yellow; margin-top: 0in;" type="1"&gt;
&lt;li class="MsoNormal"&gt;&lt;b&gt;Clinic Impact&lt;/b&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;a href="http://1.bp.blogspot.com/-taZwziEhL5o/TxyZ4NW6DAI/AAAAAAAAAC0/twJNFofY77M/s1600/blog+3.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="134" src="http://1.bp.blogspot.com/-taZwziEhL5o/TxyZ4NW6DAI/AAAAAAAAAC0/twJNFofY77M/s320/blog+3.jpg" width="320" /&gt;&lt;/a&gt;Clinical impact is a fundamental
characteristic and the most important benchmark for success of a medical device
company. Almost all firms that generate premium M&amp;amp;A exits have products
that fundamentally alter the pre-existing practice &amp;nbsp;of therapy or diagnosis. Take Perclose whose
sutere catheter provides a novel method for closing a femoral access wound. Perclose
fundamentally changed the clinical thinking and challenged the standard of care
in the cardiac cath lab (pressure with sandbags). The improvement in patient
care, comfort and clath lab efficiency were immediate. A new way of thinking
emerged , creating an entirely new market. &lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
Another recent example is Irvine, Ca based Spinofix,
Inc is working on next generation posterior fixation spine technology. Spine
surgeons in spine decompression surgery remove the spinous process, by doing
that a segment of spinal cord is exposed. Spinofix technology replaces the
spinous process and provides room for bone grafting and supposedly superior
stabilization with its fixation technology. Bigger companies are looking at
this technology as option to conventional parallel rod system.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;ol start="2" style="color: yellow; margin-top: 0in;" type="1"&gt;
&lt;li class="MsoNormal"&gt;&lt;b&gt;Franchise Value, Strategic Need &amp;amp;
     Clinical Need&lt;/b&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
Franchise value implies that a
company’s technology and the resulting clinical application are infact novel
and clearly the best of breed. In almost all cases, companies with high
franchise value are the first to market in an entirely new category. They
establish dominant presence and create a new clinical franchise.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
Eg; Lapband from Allergan is
meeting a great unmet need in the obesity space.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
Obesity is one of the biggest unmet
clinical need, and there is opportunity for 20 more companies to meet the need,
because they can target various methods to treat obesity.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;ol start="3" style="color: yellow; margin-top: 0in;" type="1"&gt;
&lt;li class="MsoNormal"&gt;&lt;b&gt;The Effect of Focusing on Milestones/
     Value of Execution&lt;/b&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
The company’s performance during
the early stages of its development is critical to maximizing value. This
explains why VCs place so much emphasis on the management team. Not only is
execution important, it is controllable; an experienced team knows how to
organize itself around key issues, thereby preventing situations such as
program misdirection and lack of appropriate development focus from taking
hold, while at the same time preserving the ability to change direction based
on new information. Good start ups have good strategy.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;ol start="4" style="color: yellow; margin-top: 0in;" type="1"&gt;
&lt;li class="MsoNormal"&gt;&lt;b&gt;Sustainability&lt;/b&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
When buying a company, models are
built to justify acquisition or an IPO, placing extensive weigh on sustainable
(if IPO) or predicatable sales (start up) of the acquired technology. Buyers want
to know whether acquiring a company or its technology (product acquisition) is
going to generate long –lasting profits.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
A large market, significant
clinical impact and the ability to bolster a franchise for the acquirer is
critical to profit sustainability. It signifies successful management of
capital and time.&lt;/div&gt;
&lt;div class="MsoNormal" style="color: yellow; margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;ol start="5" style="color: yellow; margin-top: 0in;" type="1"&gt;
&lt;li class="MsoNormal"&gt;&lt;b&gt;Timing of Exit &lt;/b&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
A company with a ground breaking
technology may exit too early. &amp;nbsp;It is
important to monitor progress against milestones and the impact. Exiting before
hitting the infliction point will result in less money and less ROI for
investors. Conversely, &amp;nbsp;if the infliction
point is not noticed and value is not cashed, then a opportunity to exit may be
lost. Therefore timing is very important, monitoring the infliction point may
bring very high return on investment or a good exit.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;a href="http://2.bp.blogspot.com/-v6ogQIy-5gc/TxygNTL3R2I/AAAAAAAAAC8/Ufv84PD3Syc/s1600/blog+6.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="307" src="http://2.bp.blogspot.com/-v6ogQIy-5gc/TxygNTL3R2I/AAAAAAAAAC8/Ufv84PD3Syc/s320/blog+6.jpg" width="320" /&gt;&lt;/a&gt;In the past four years the inflow
of money from VCs into early start ups has affected the way exits will occur.
Milestones are slower, but the key is “who stays in the game” companies who run
out of money or spend it too fast to reach milestone can lose because they are
not in the game. &amp;nbsp;Startups need to manage
regulatory and clinical strategy to manage more complex FDA interaction. &lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
The good news is the M&amp;amp;A market
is very strong, large cap companies still depend on small medical device
companies as a source to expand their offerings without earning dilutions, and
funding will therefore continue to be available for novel, clinically relevant
products that serve large and growing markets, one example is obesity market. Obesity
was a condition and recently categorized as a disease, there are very few
players and will continue to be the biggest market in the world as US, UK,
AUSTRALIA, EU, LATIN AMERICA all reel under epidemic of obesity and its
problems. This is a $200B market and growing.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
The above benchmark characteristics
define a successful value creation and exit.&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
By: Raj Nihalani, M.D., RAC(US) &lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal" style="margin-left: 0.5in;"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class="MsoNormal"&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-6182471556080035310?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/6182471556080035310/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=6182471556080035310' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/6182471556080035310?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/6182471556080035310?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/normal-0-false-false-false.html' title='5 Ways of Creating High Valuations for Your Life Science Company'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-taZwziEhL5o/TxyZ4NW6DAI/AAAAAAAAAC0/twJNFofY77M/s72-c/blog+3.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DkADRn0ycSp7ImA9WhRUEkw.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-3200889447025394752</id><published>2012-01-21T22:46:00.000-08:00</published><updated>2012-01-21T22:46:17.399-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-21T22:46:17.399-08:00</app:edited><title>Burrill makes the following predictions for life science sector for 2012</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;b&gt;Burrill makes the following predictions for life science sector for 2012:&lt;/b&gt;&lt;br /&gt;
2011  has been a year of investments as most public and private life science  companies raised a fund which was up to $76.2 billion. The ongoing  volatility in the market is not very promising for the companies which  want to raise their fund through public markets but the market will  slowly gain stability and will be favorable for investments in 2012. In  2012, many biotech companies are said to go public through initial  public offering (IPO) to raise expansion funds. More IPO activity is  expected the coming year. Consumer based technology companies will be  the ones topping the list of the IPOs. About 25 life sciences companies  are expected to hit the listings in 2012.&lt;br /&gt;
Private investments in  life sciences will exceed around 10 percent in 2012. Traditional funding  by venture capitals, angel capitals, and other private sources of  funding will continue to be the major sources of investments.  Traditional venture investors will be funding more for exploration of  areas in medical science ranging from therapeutics to other areas of  healthcare.&amp;nbsp; More funds will be allotted for medical device sector to  benefit particularly the aging population for more wireless devices.&lt;br /&gt;
2012  will witness a major lift in M&amp;amp;A (mergers and acquisitions) as  several small-medium bio tech companies are gearing up activity for  combined research and products which will pose as a competition for the  big players in the industry. They will have to continue to distinguish  sectors under them based on pharmaceutical, biotech, generic,  biosimilars, and diagnostics. And one of the ways to achieve this is  through aggressive buying of innovative companies.&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-3200889447025394752?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/3200889447025394752/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=3200889447025394752' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/3200889447025394752?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/3200889447025394752?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/burrill-makes-following-predictions-for.html' title='Burrill makes the following predictions for life science sector for 2012'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DE4CRHs6eyp7ImA9WhRVF0o.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8293081182687699199</id><published>2012-01-16T21:09:00.000-08:00</published><updated>2012-01-16T21:09:25.513-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-16T21:09:25.513-08:00</app:edited><title>Maryland VCs are moving their cash into medical devices- Medical Tech Boom</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState="false" LatentStyleCount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if !mso]&gt;&lt;img src="http://img2.blogblog.com/img/video_object.png" style="background-color: #b2b2b2; " class="BLOGGER-object-element tr_noresize tr_placeholder" id="ieooui" data-original-id="ieooui" /&gt; &lt;style&gt;
st1\:*{behavior:url(#ieooui) }
&lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-parent:"";
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin:0in;
 mso-para-margin-bottom:.0001pt;
 mso-pagination:widow-orphan;
 font-size:10.0pt;
 font-family:"Times New Roman";
 mso-ansi-language:#0400;
 mso-fareast-language:#0400;
 mso-bidi-language:#0400;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class="MsoNormal"&gt;In Maryland, venture capitalists are moving their cash into medical devices, despite a blip in investing &amp;amp; global market retrenching.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;VC firms have invested a record $47 million in Maryland’s makers of medical devices and equipment, according to the latest venture capital report published by PricewaterhouseCoopers&lt;span&gt;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;That figure towers over the mere $4.6 million invested in the industry in all of 2010, and it’s second-most among all industries in Maryland so far this year. More than $52 million has been invested in biotechnology through 2011.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;What’s going on in Maryland appears to be taking place across the country, too. Venture firms invested $728 million in 74 deals with the medical device industry. That’s a 17 percent increase in the amount of money invested in devices&lt;/div&gt;&lt;div class="MsoNormal"&gt;This is an indication of a medical device boom all over the country and in emerging countries. &lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8293081182687699199?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8293081182687699199/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8293081182687699199' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8293081182687699199?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8293081182687699199?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/maryland-vcs-are-moving-their-cash-into.html' title='Maryland VCs are moving their cash into medical devices- Medical Tech Boom'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DEAEQHc8cSp7ImA9WhRVFU4.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-2585204511620388243</id><published>2012-01-14T02:25:00.000-08:00</published><updated>2012-01-14T02:25:01.979-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-14T02:25:01.979-08:00</app:edited><title>Medical Technology’s biggest wheeling-and-dealing session, the 30th annual J.P. Morgan Healthcare Conference in San Francisco.</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState="false" LatentStyleCount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if !mso]&gt;&lt;img src="http://img2.blogblog.com/img/video_object.png" style="background-color: #b2b2b2; " class="BLOGGER-object-element tr_noresize tr_placeholder" id="ieooui" data-original-id="ieooui" /&gt; &lt;style&gt;
st1\:*{behavior:url(#ieooui) }
&lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-parent:"";
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin:0in;
 mso-para-margin-bottom:.0001pt;
 mso-pagination:widow-orphan;
 font-size:10.0pt;
 font-family:"Times New Roman";
 mso-ansi-language:#0400;
 mso-fareast-language:#0400;
 mso-bidi-language:#0400;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class="MsoNormal"&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;Over 9,000 people attended the meeting, Wall Street folks, VCs, Entrepreneurs, CEOs, innovators, physicians. Folks attending the meeting had to show their invitation confirmations, those staying at the hotel had to show their room keys, so the security crush significantly cut down “clock tower” meetings in the hotel’s lobby. Coupled with the unusually good January weather, Union Square became the preferred chat-up locale, to the point that the park was overrun by posses of (mostly) men in black suits. This is where attendees (investors) figure out where they’re going to put their money in the year. &lt;/div&gt;&lt;div class="MsoNormal"&gt;In side the St Francis Hotel. The Investment community was bullish on the prospects of the med tech sector in 2012 despite the fact that the medtech industry concerns have not permeated the FDA.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;One of the positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of investment banking for North America, that the U.S. economy would grow 2.5 percent in 2012&lt;a href="http://2.bp.blogspot.com/-MFh6mF5x_I8/TxFXYfX0XkI/AAAAAAAAACM/DbPARJnMAtw/s1600/Maria+Bartiromo.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="200" src="http://2.bp.blogspot.com/-MFh6mF5x_I8/TxFXYfX0XkI/AAAAAAAAACM/DbPARJnMAtw/s200/Maria+Bartiromo.jpg" width="140" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;In the opening remarks of Jamie Dimon, J.P.Morgan’s Chairman and CEO. In a Q&amp;amp;A with &lt;b&gt;Maria Bartiromo&lt;/b&gt;, Anchor of CNBC’s “Closing Bell,” Dimon mentioned that he saw hope despite the sobering challenges faced by the industry and the country.&lt;/div&gt;&lt;div class="textbodyblack"&gt;Dimon on Economy: &lt;/div&gt;&lt;div class="textbodyblack"&gt;&lt;span id="byLine"&gt;&lt;/span&gt;PEOPLE WANT TO GROW, THEY WANT TO EXPAND. THE INNOVATION AND TALENT OF THESE COMPANIES IS EXTRAORDINARY. AND YEAH, I THINK WE'RE STARTING TO SEE THE WORLD RETURN TO A GOOD, NORMAL, LET'S INVEST, LET'S TAKE RISKS, LET'S GROW AND FIND NEW PRODUCTS AND SERVICES. I THINK THAT'S A GREAT THING&lt;/div&gt;&lt;div class="MsoNormal"&gt;&amp;nbsp;&lt;/div&gt;&lt;div class="MsoNormal"&gt;The sentiment of the CEOs and executives from EU and Asia showed promise and growing demand in health care across EU and Asia. China added over 10,000 hospitals last year, and continues to build. This has created demand and respect for new technologies and innovations. China and the emerging markets are encouraging innovators to seek funding in their countries if the regulatory environment is not apt for innovation in the US. &lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;Other news:&lt;/div&gt;&lt;ul style="margin-top: 0in;" type="disc"&gt;&lt;li class="MsoNormal"&gt;Bristol-Myers      Squibb’s $2.5 billion purchase of Inhibitex.&lt;/li&gt;
&lt;li class="MsoNormal"&gt;Increase      in the awareness for treatments of Obesity and Diabetes using drugs and medical      devices. Investors showed renewed interest in the Diabetes and Obesity      treatments &lt;/li&gt;
&lt;li class="MsoNormal"&gt;Abbott      CFO Thomas Freyman provided lots of details, which he dutifully read,      about the planned split of the company into two — pharmaceutical and      medical products companies. Medical devices will contribute about 27% of      Abbott's (NYSE:&lt;a href="http://www.google.com/finance?q=abt" target="_blank" title="Abbott stock ticker"&gt;ABT&lt;/a&gt;) sales after it spins      out its research pharmaceuticals unit later this year, CFO Thomas Freyman      said&lt;/li&gt;
&lt;li class="MsoNormal"&gt;AstraZeneca’s      CFO Simon Lowth provided a change of themes as he placed the importance of      partnering as a primary plank of his pitch. He portrayed AZ as a “focused,      innovation-driven, integrated global biopharmaceutical company.”&lt;/li&gt;
&lt;li class="MsoNormal"&gt;Former      FDA Commissioner Mark McClelland, in a luncheon presentation on Wednesday,      also gave hope for some good coming from the Affordable Health Act. He      stated strongly that “the law was very unlikely to go away.” He foresaw      2012 as a very important year for financial discussions focused much more      on the “value” of health care, regulatory reforms and more effective      health care.&lt;/li&gt;
&lt;li class="MsoNormal"&gt;The      lack of sufficient funding for new start-ups, perhaps the largest      “elephant in the room” and a major cause of feelings of uncertainty among      entrepreneurs, also went unaddressed. Yet it was the focus of many quiet      conversations in the hallways. Start-up company founders and supporters      shared experiences of finding the “VC wells dry,” greater difficulty in      winning NIH grants and scrambling to line up alternative funding sources.      Some looked to other conferences in town for answers to these important questions.&lt;/li&gt;
&lt;/ul&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;The buzz here this year is all about: (1) innovation: a year jam-packed with new milestones (2) collaboration: academia, pharma, biotechs, medical device makers, VCs, non-profits (3) deal-making: pace of deals is likely to pick up as big pharma looks to replenish pipelines.&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-2585204511620388243?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/2585204511620388243/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=2585204511620388243' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2585204511620388243?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/2585204511620388243?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/medical-technologys-biggest-wheeling.html' title='Medical Technology’s biggest wheeling-and-dealing session, the 30th annual J.P. Morgan Healthcare Conference in San Francisco.'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-MFh6mF5x_I8/TxFXYfX0XkI/AAAAAAAAACM/DbPARJnMAtw/s72-c/Maria+Bartiromo.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;C0QERnk_cCp7ImA9WhRVFU4.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-6998806528136654347</id><published>2012-01-14T00:55:00.000-08:00</published><updated>2012-01-14T00:55:07.748-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-14T00:55:07.748-08:00</app:edited><title>Top Five Indicators That Will Transform Medicine</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState="false" LatentStyleCount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if !mso]&gt;&lt;img src="http://img2.blogblog.com/img/video_object.png" style="background-color: #b2b2b2; " class="BLOGGER-object-element tr_noresize tr_placeholder" id="ieooui" data-original-id="ieooui" /&gt; &lt;style&gt;
st1\:*{behavior:url(#ieooui) }
&lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-parent:"";
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin:0in;
 mso-para-margin-bottom:.0001pt;
 mso-pagination:widow-orphan;
 font-size:10.0pt;
 font-family:"Times New Roman";
 mso-ansi-language:#0400;
 mso-fareast-language:#0400;
 mso-bidi-language:#0400;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class="MsoNormal"&gt;&lt;b&gt;&lt;span style="color: #003366; font-size: 18pt;"&gt;&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://3.bp.blogspot.com/-WGXnuMQZY04/TxFBzBPSFKI/AAAAAAAAACE/ta8-gMhCguU/s1600/wt+loss+jan+2012.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="152" src="http://3.bp.blogspot.com/-WGXnuMQZY04/TxFBzBPSFKI/AAAAAAAAACE/ta8-gMhCguU/s200/wt+loss+jan+2012.jpg" width="200" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in;"&gt;&lt;b&gt;&lt;span&gt;1.&lt;span style="font: 7pt &amp;quot;Times New Roman&amp;quot;;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;Identifying the unmet clinical need. &lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Today the #1 preventive causes of death is Obesity. US spends over $150 Billion in direct and indirect cost to treat obesity and obesity related problems. There are no therapies to provide durable weight loss. Diet and exercise alone cannot help the patients. Many patients who have comorbidities and need to lose more than 50lbs are looking at bariatric surgery. Today, there are surgical procedures that are effective than drugs. US gov needs to support companies that are focused on providing treatment for obesity. 90 Mil people are obese in US, of which 50% need some kind of medical intervention, 14 Mil people are medicare approved to get a surgical intervention and assume a medical device cost $8000 to $10,000&lt;span&gt;&amp;nbsp; &lt;/span&gt;it is a $140 Billion market in US alone. At the recent JP Morgan Health Care Conference 2012, there was a renewed interest in Obesity interventions. VCs and companies are looking at new technologies to fund. It is predicted that Obesity will be the biggest medical device market in this decade. There is opportunity for 50 more companies in this space.&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in;"&gt;&lt;b&gt;&lt;span&gt;2.&lt;span style="font: 7pt &amp;quot;Times New Roman&amp;quot;;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;The US FDA and the industry need to work together.&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;The US medical device, drug and biologics innovation is in danger because the regulations are too strict, stringent and one sided. &lt;b&gt;The industry has recommended the FDA to create methods where the companies can provide ample data to show safety of the product and get provisional approval, to enable the innovation to reach the needy patients in the US. The industry has also suggested that post marketing studies can define effectiveness. This way the industry can bring innovations to the health care providers and patients. This is a simple and reasonable solution for both the FDA and the industry, and someone in the US FDA and the White House must pay attention to the above suggestions.&lt;br /&gt;
&lt;/b&gt;FDA has taken the role of playing “&lt;i&gt;Dr&lt;/i&gt;” was the sentiment at the recent JP Morgan health care conference in Jan 2012. “&lt;i&gt;FDA needs to soften its approach and industry will stop complaining&lt;/i&gt;” said a young medical device manufacturer. &lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;The above suggestions were brought to the notice of the speakers representing the FDA at the Jan 2012 JP Morgan Health Care Conference. The response was “FDA is not going to imitate EU regulations”&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Today, there is a real threat of innovation moving outside US soil, if that happens, US will no longer be using cutting edge medical technology to treat patients. Emerging countries will dominate in medicine and technology. &lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;2012 is an election year. Medical, investment and pharma community is huge and is waiting to see actions before the elections so they can decide who to vote for. &lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in;"&gt;&lt;b&gt;&lt;span&gt;3.&lt;span style="font: 7pt &amp;quot;Times New Roman&amp;quot;;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;Practicing Social &amp;amp; Preventative Health.&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Public needs to pay more attention to their social and personal health practices. Have a small budget for buying vitamins and healthy foods. Make sure that the immunization shots are taken regularly, diet and exercise is part of the daily conversation. Kids are exposed to vegetables and good nutrition, exposed to sunlight, good personal hygiene, just washing hands can prevent infections.&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in;"&gt;&lt;b&gt;&lt;span&gt;4.&lt;span style="font: 7pt &amp;quot;Times New Roman&amp;quot;;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;Opportunity&lt;/b&gt;&lt;b&gt; to open patient portals:&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Consumers should be able to connect with health care providers and check appointments, see lab results, renew prescriptions, and communicate with doctors and nurses. The HIPAA regulation needs to be reviewed to make sure it does not cost us more because the health information was not available on time to treat the patient.&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;&lt;b&gt;Privacy of health care info is a good thing, but if people are openly discussing everything on facebook, what is the point of HIPAA? Is this not making health care expensive?&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in;"&gt;&lt;b&gt;&lt;span&gt;5.&lt;span style="font: 7pt &amp;quot;Times New Roman&amp;quot;;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;Reform HIPAA: Health Insurance Portability &amp;amp; Accountability Act&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;If everyone, is chatting about everything on Facebook and twitter and other social media. Why are we worried about privacy of health records? The access to these records is so difficult that, in a medical emergency the patients have to go through a whole battery of test, because his or her recent records were not available in time. The cost burden is on the subscribers.&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Is this not adding to the health care cost America? This is more expensive and think about it, very risky! If important history is not available, it can result in sad or unnecessary outcomes. Reach out to the White House or your local representative.&lt;/div&gt;&lt;div class="MsoNormal" style="margin-left: 0.25in;"&gt;Or one day affording health care will be a dream. Privacy is needed but within reason.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-6998806528136654347?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/6998806528136654347/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=6998806528136654347' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/6998806528136654347?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/6998806528136654347?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/top-five-indicators-that-will-transform.html' title='Top Five Indicators That Will Transform Medicine'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/-WGXnuMQZY04/TxFBzBPSFKI/AAAAAAAAACE/ta8-gMhCguU/s72-c/wt+loss+jan+2012.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;CkMARHo_eSp7ImA9WhRWGUU.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-5547500517833265272</id><published>2012-01-07T15:15:00.000-08:00</published><updated>2012-01-07T15:54:05.441-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-07T15:54:05.441-08:00</app:edited><title>Resources for Med Tech Innovators</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-left: 0px; margin-right: 0px; text-align: left; width: 837px;"&gt;&lt;tbody&gt;
&lt;tr align="left" valign="top"&gt;&lt;td&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 608px;"&gt;&lt;tbody&gt;
&lt;tr align="left" valign="top"&gt;&lt;td class="TextObject" width="571"&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;b&gt;&lt;span style="font-size: 12pt;"&gt;&lt;span style="font-size: large;"&gt;MEDICAL TECHNOLOGY INNOVATION &amp;amp; INVESTMENT JOURNAL&lt;/span&gt;&amp;nbsp;&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;b&gt;&lt;span style="font-size: 12pt;"&gt;Is working on identifying and bringing as many resources to med tech professionals to make their start ups successful.&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;b&gt;&lt;span style="font-size: 12pt;"&gt;The following list of companies have some history of bringing investments in to&amp;nbsp; startups in the med tech sector.&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;b&gt;&lt;span style="font-size: 12pt;"&gt;&lt;br /&gt;
&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;b&gt;&lt;span style="font-size: 12pt;"&gt;&lt;span style="font-size: large;"&gt;&lt;span style="color: blue;"&gt;York Medtech Partners Inc.&lt;/span&gt;&lt;/span&gt;, &lt;span style="font-weight: normal;"&gt;&lt;span style="font-size: 10pt;"&gt;based in Toronto&lt;/span&gt;, &lt;span style="font-size: 10pt;"&gt;Canada,&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,Serif,serif;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style="font-size: 10pt;"&gt;is  an advisory and investment firm serving companies in the medical  technology sector. They work with high potential technology companies in  the following areas:&lt;/span&gt;&lt;/div&gt;&lt;ul&gt;&lt;li style="text-align: justify;"&gt;Medical devices&lt;/li&gt;
&lt;li style="text-align: justify;"&gt;Medical Imaging&lt;/li&gt;
&lt;li style="text-align: justify;"&gt;Medical diagnostics&lt;/li&gt;
&lt;li style="text-align: justify;"&gt;Health science instrumentation&lt;/li&gt;
&lt;li style="text-align: justify;"&gt;E-health technologies&lt;/li&gt;
&lt;li style="text-align: justify;"&gt;Healthcare services&lt;/li&gt;
&lt;/ul&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;York&amp;nbsp; partners with management, entrepreneurs, researchers, and investors to  create and build medical technology businesses with global reach. Their  team contributes management expertise, industry knowledge and access to  capital to transform great ideas into successful commercial ventures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;York  Medtech Partners has established York Medtech Commercialization Fund  (YMCF) to make seed stage investments in medical technology companies  arising from Ontario research institutions. Eligible investments by YMCF  qualify for a 30% grant from the Ontario Government. YMCF is sponsored  by several of Canada’s premier research institutions including the  University of Toronto, York University, University of Waterloo,  University of Western Ontario, University of Ottawa and Sunnybrook  Health Sciences Centre.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;Contact:&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="font-size: 11pt;"&gt;Office Location&lt;/span&gt;&lt;/b&gt;595 Bay St., Suite 1204&lt;br /&gt;
P.O. 75&lt;br /&gt;
Toronto, Ontario, CANADA&lt;br /&gt;
M5G 2C2&lt;br /&gt;
Phone: (416) 482-6568&lt;br /&gt;
Fax: (416) 640-5153&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;John Connolly - Managing Director&lt;/b&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br /&gt;
Direct: (416) 985-4361&lt;br /&gt;
Email: &lt;a href="mailto:jconnolly@yorkmp.com"&gt;&lt;span style="font-size: 11pt;"&gt;jconnolly@yorkmp.com&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="font-size: 11pt;"&gt;Ken Pritzker - Managing Director&lt;/span&gt;&lt;/b&gt;&lt;br /&gt;
Direct: (647) 221-6909 &lt;br /&gt;
Email: &lt;a href="mailto:kpritzker@yorkmp.com"&gt;&lt;span style="font-size: 11pt;"&gt;kpritzker@yorkmp.com&lt;/span&gt;&lt;/a&gt; &lt;span style="font-size: 11pt;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="font-size: 11pt;"&gt;John Jordan - Director&lt;/span&gt;&lt;/b&gt;&lt;br /&gt;
Direct: (416) 729-7502&lt;br /&gt;
Email: &lt;a href="mailto:jjordan@yorkmp.com"&gt;&lt;span style="font-size: 11pt;"&gt;jjordan@yorkmp.com&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="color: blue; text-align: left;"&gt;&lt;span style="font-size: large;"&gt;&lt;b&gt;END&lt;/b&gt;&lt;b&gt;EAVOUR VISION&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;are a venture and growth capital firm providing expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;. The company is based in Switzerland. They have funded the technologies that can be disruptive.&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;&lt;br /&gt;
&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;b&gt;Endeavour Vision SA&lt;br /&gt;
6 rue de la Croix d’Or&lt;br /&gt;
1204 Geneva, Switzerland&lt;br /&gt;
Tel +41 22 544 6000&lt;br /&gt;
info@endeavourvision.com&lt;br /&gt;
&lt;a href="http://www.blogger.com/goog_1616006514"&gt;www.endeavourvision.com&lt;/a&gt;&lt;/b&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="color: blue; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;&lt;span style="font-size: large;"&gt;TrialM&lt;a href="http://www.trialmed.com/"&gt;ed Life Sciences, LLC&lt;/a&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;The group is connected to distributors in India and have a team to do a clinical trial on medical devices in INDIA.&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;contact: &lt;a href="mailto:sonali@trialmed.com"&gt;sonali@trialmed.com&lt;/a&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="color: blue; text-align: left;"&gt;&lt;span style="font-size: large;"&gt;&lt;b&gt;The Mercury Medical Investments (MMI)&amp;nbsp;&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;This group provides early stage funding for promising healthcare and healthcare related technology.&amp;nbsp; &lt;br /&gt;
&lt;br /&gt;
They identify investments aligned with their mission to improve healthcare and patient outcomes through innovation and technology, while striving to achieve excellent returns for their investors.&lt;br /&gt;
&lt;br /&gt;
Once identified and screened, we seed the early stage companies and provide financing, guidance, and networking to help the venture achieve benchmarks to success.&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;&amp;nbsp;Submit your business plan and supporting materials to:&amp;nbsp; &lt;a href="mailto:getstarted@mercmed.com"&gt;getstarted@mercmed.com&lt;/a&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;h1 id="topofpage" style="color: blue;"&gt;&lt;span style="font-size: large;"&gt;AIB Venture Capital Fund&lt;/span&gt;&lt;/h1&gt;As part of our comprehensive range of financing options,  AIB also provides Venture Capital funding to Irish businesses in the  early stages of their development.&amp;nbsp; The AIB Seed Capital Fund which is  co-owned by both AIB Bank and Enterprise Ireland is the largest Seed  Capital fund in the country.&amp;nbsp; Established in 2007 a total of almost EUR7  million has been invested in 18 projects (to June 2009) and the fund is  expected to substantially increase the level of investments over the  next three years.&lt;br /&gt;
&lt;br /&gt;
The average initial investment made by the Fund is in the order of  EUR250,000 but smaller investments of EUR100,000 will also be  evaluated.&lt;br /&gt;
&lt;br /&gt;
Enquiries from all sectors are welcome and to date enquiries have  predominantly come from Entrepreneurs in the internet, software and  services sectors along with enquiries from the marine, media, healthcare  and food sectors from all across Ireland.&lt;br /&gt;
&lt;br /&gt;
If your business or business idea is in need of a cash injection, then the AIB Seed Capital Fund may be the solution.&lt;br /&gt;
&lt;h2&gt;&lt;span style="font-size: small;"&gt;How the Venture Capital Funds work:&lt;/span&gt;&lt;/h2&gt;&lt;ul class="unorderedList"&gt;&lt;li&gt;The Venture Capital Fund provides money for investment in innovative enterprises in exchange for a stake in the enterprise.&lt;/li&gt;
&lt;li&gt;Venture Capital investments are usually for a period of 3-5 years at  which stage there is normally an IPO, a merger, an acquisition or a  buy-out.&lt;/li&gt;
&lt;/ul&gt;&lt;h2&gt;&lt;span style="font-size: small;"&gt;Benefits of Venture Capital Funds:&lt;/span&gt;&lt;/h2&gt;&lt;b&gt;An excellent source of finance&lt;/b&gt;&lt;br /&gt;
Venture Capital finance gives your business a cash injection to fund  expansion, product development or acquisition. Unlike more traditional  forms of finance periodic interest payments are not expected of a  company invested in by the Venture Capital Fund. Additionally, this form  of financing may be available to your business when other forms of  finance are not.&lt;br /&gt;
&lt;br /&gt;
&lt;b&gt;Expertise and advice&lt;/b&gt;&lt;br /&gt;
The expertise and advice of the venture capitalists is at your  disposal. This could range from offering you commercial and strategic  advice, a network of business contacts, assistance with staff and  management development, fundraising or marketing.&lt;br /&gt;
&lt;h2&gt;&lt;span style="font-size: small;"&gt;How to apply:&lt;/span&gt;&lt;/h2&gt;Details of the AIB Seed Capital Fund and the application process can be found on &lt;a href="http://www.aibseedcapitalfund.ie/" target="blank"&gt;www.aibseedcapitalfund.ie&lt;/a&gt; and on the websites of the Investment Managers; &lt;a href="http://www.enterpriseequity.ie/" target="blank"&gt;www.enterpriseequity.ie&lt;/a&gt; and &lt;a href="http://www.dbic.ie/" target="blank"&gt;www.dbic.ie&lt;/a&gt;.&lt;br /&gt;
&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;&amp;nbsp; &lt;br /&gt;
&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 11pt;"&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;         &lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;       &lt;td&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 229px;"&gt;&lt;tbody&gt;
&lt;tr align="left" valign="top"&gt;          &lt;td height="53" width="58"&gt;&lt;img alt="" border="0" height="1" src="http://yorkmedtechpartnersinc.com/assets/images/autogen/clearpixel.gif" width="58" /&gt;&lt;/td&gt;          &lt;td&gt;&lt;br /&gt;
&lt;/td&gt;         &lt;/tr&gt;
&lt;tr align="left" valign="top"&gt;          &lt;td height="223"&gt;&lt;br /&gt;
&lt;/td&gt;          &lt;td width="171"&gt;&lt;img alt="Picture1" border="0" height="223" id="Picture4" src="http://yorkmedtechpartnersinc.com/assets/images/Picture1.jpg" title="Picture1" width="171" /&gt;&lt;/td&gt;         &lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;/td&gt;      &lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-left: 0px; margin-right: 0px; text-align: left;"&gt;&lt;tbody&gt;
&lt;tr align="left" valign="top"&gt;&lt;td height="25" width="13"&gt;&lt;img alt="" border="0" height="1" src="http://yorkmedtechpartnersinc.com/assets/images/autogen/clearpixel.gif" width="13" /&gt;&lt;/td&gt;       &lt;td&gt;&lt;br /&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-5547500517833265272?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/5547500517833265272/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=5547500517833265272' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5547500517833265272?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5547500517833265272?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/resources-for-med-tech-innovators.html' title='Resources for Med Tech Innovators'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DUEHRHw8fyp7ImA9WhRWGE0.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-1455844982073817338</id><published>2012-01-05T15:53:00.000-08:00</published><updated>2012-01-05T15:53:55.277-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2012-01-05T15:53:55.277-08:00</app:edited><title>Medical Technology Outlook for 2012</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"&gt;&lt;img alt="" height="271" src="data:image/jpeg;base64,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" width="400" /&gt;&amp;nbsp;&lt;/div&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:OfficeDocumentSettings&gt;   &lt;o:AllowPNG/&gt;  &lt;/o:OfficeDocumentSettings&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:TrackMoves/&gt;   &lt;w:TrackFormatting/&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:DoNotPromoteQF/&gt;   &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:LidThemeComplexScript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;    &lt;w:SplitPgBreakAndParaMark/&gt;    &lt;w:EnableOpenTypeKerning/&gt;    &lt;w:DontFlipMirrorIndents/&gt;    &lt;w:OverrideTableStyleHps/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathPr&gt;    &lt;m:mathFont m:val="Cambria Math"/&gt;    &lt;m:brkBin m:val="before"/&gt;    &lt;m:brkBinSub m:val="&amp;#45;-"/&gt;    &lt;m:smallFrac m:val="off"/&gt;    &lt;m:dispDef/&gt;    &lt;m:lMargin m:val="0"/&gt;    &lt;m:rMargin m:val="0"/&gt;    &lt;m:defJc m:val="centerGroup"/&gt;    &lt;m:wrapIndent m:val="1440"/&gt;    &lt;m:intLim m:val="subSup"/&gt;    &lt;m:naryLim m:val="undOvr"/&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="267"&gt;   &lt;w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/&gt;   &lt;w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/&gt;   &lt;w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 1"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 2"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 3"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 4"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 5"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 6"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 7"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 8"/&gt;   &lt;w:LsdException Locked="false" Priority="39" Name="toc 9"/&gt;   &lt;w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/&gt;   &lt;w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/&gt;   &lt;w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/&gt;   &lt;w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/&gt;   &lt;w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/&gt;   &lt;w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/&gt;   &lt;w:LsdException Locked="false" Priority="59" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/&gt;   &lt;w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/&gt;   &lt;w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/&gt;   &lt;w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/&gt;   &lt;w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/&gt;   &lt;w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/&gt;   &lt;w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/&gt;   &lt;w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/&gt;   &lt;w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/&gt;   &lt;w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/&gt;   &lt;w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/&gt;   &lt;w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/&gt;   &lt;w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/&gt;   &lt;w:LsdException Locked="false" Priority="37" Name="Bibliography"/&gt;   &lt;w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-parent:"";
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:"Calibri","sans-serif";
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:"Times New Roman";
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class="MsoNormal"&gt;So here’s a look at America’s prospects for 2012. The economy might be headed for a stronger growth track, but there are least three potential obstacles to watch for: Europe, China and political gridlock.&lt;/div&gt;&lt;div class="MsoNormal"&gt;US seems to have de-coupled with Europe and its troubles.&lt;/div&gt;&lt;div class="MsoNormal"&gt;First the positive signs, of which there are plenty: the jobs market is looking up, housing sales and construction have been showing recent signs of improvement, business sales and profits are rising.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;It appears that the Life Science and the IT industry will be the leading sectors in 2012.&lt;/div&gt;&lt;div class="MsoNormal"&gt;US Pharma and the med tech companies are cash rich. All life science M&amp;amp;A activity has been strong. &lt;/div&gt;&lt;div class="MsoNormal"&gt;Now, as the FDA starts showing the improvements in their processes. The Med tech industry is showing signs of a boom. See the trend in the early stage investments in the med tech sector from 1994 to 2011. The amount of investments is going up since its peak in 2008.&lt;/div&gt;&lt;div class="MsoNormal"&gt; The JP Morgan Health Care Conference meeting in San Francisco will be attended by entrepreneurs and investors from the US and abroad.The health care need in the treatments of Obesity, Diabetes, Orthopedic and Spine Implants, Cardio-Vascular products, Personalized e-health, Diagnostics&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;i&gt;What is holding back the surge in life Science Industry is: US FDA&lt;/i&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;Industry experts suggest that:&amp;nbsp; FDA needs to "not play physician" and let physicians plan the patient treatments and decide what is best for their patients. The European MDD (Medical Device Directive) is the fair example. If the FDA regulators understand that health care is subjective and many patients are being deprived of new technology because of the red tape at the FDA. Bottom line, if companies have a ISO 13585 certification, FDA should approve the product in the US market. This will enable the patients have access to a wide variety of treatment options and it will be great for the life science industry.&lt;/div&gt;&lt;div class="MsoNormal"&gt;&amp;nbsp; &lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-1455844982073817338?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/1455844982073817338/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=1455844982073817338' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1455844982073817338?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1455844982073817338?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2012/01/medical-technology-outlook-for-2012.html' title='Medical Technology Outlook for 2012'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DkcDSHk8fyp7ImA9WhRXF0o.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-177979935972079016</id><published>2011-12-24T16:47:00.000-08:00</published><updated>2011-12-24T16:47:59.777-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-12-24T16:47:59.777-08:00</app:edited><title>India Forecast: Use of Medical Procedures Will Double by 2013</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;h2&gt;&lt;a href="http://india.medtechinsider.com/archives/593" rel="bookmark" title="Permanent Link: Number of Surgical Procedures in India Forecast to Double by 2013"&gt;Use of Medical Procedures Double by 2015 &lt;/a&gt;&lt;/h2&gt;&lt;abbr title="2011-07-18T18:52:34+0000"&gt;&lt;/abbr&gt;         &lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://2.bp.blogspot.com/-x8x4QIIRsnU/TvZq5qk4J3I/AAAAAAAAAB4/17aMjniwiHQ/s1600/BRIC1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="220" src="http://2.bp.blogspot.com/-x8x4QIIRsnU/TvZq5qk4J3I/AAAAAAAAAB4/17aMjniwiHQ/s400/BRIC1.jpg" width="400" /&gt;&lt;/a&gt;&lt;/div&gt;Almost 17 million surgical procedures were performed in India in  2009, achieving an annual growth rate exceeding 18%, according to TrialMed India. Driven largely by the private sector, the volume of surgical procedures is set to double by 2013.&lt;span id="more-593"&gt;&lt;/span&gt;&lt;br /&gt;
Indians are facing a life time epidemic in Diabetes, weight gain, metabolic syndrome. The procedures in OB/GYN and ophthalmic interventions accounted for a staggering 87% of  the surgical procedures performed in 2009. Ophthalmic procedures are  disproportionately high in India because of a large population with  reversible blindness: 12 million Indians are estimated to suffer from  preventable or reversible blindness. Not-for-profit hospitals  specialised in eye care provide treatment to the poor, with an estimated  5.3 million cataract removal surgeries and intraocular lens  implantations performed in 2009.&lt;br /&gt;
&lt;br /&gt;
Caesarean section delivery is the main OB/GYN surgery performed. It  is estimated that almost two in three births conducted in private  hospitals in urban Indian cities are performed using this procedure. The  popularity of C-section deliveries is partly because private hospitals  encourage patients to choose it as it provides a higher profit margin  than vaginal delivery, but also because educated and affluent Indian  women are opting for a C-section to avoid pain during delivery.&lt;br /&gt;
&lt;br /&gt;
The increase use of coronary stents. India will become one of the biggest markets to use treatments to curb diabetes in the form of medical device implants like GI Dynamics, VallantX, Onciomed, Allergan, J&amp;amp;J products. Medtronic has an insulin pump, but may not have anthing in the weight loss market which solves the diabetes and weight loss problem-short term or long term.&lt;br /&gt;
Estimated over 30 million Indians will be pre diabetic or diabetic by 2015. A third of them will need weight loss treatments like the lapband or other weight loss devices. &lt;b&gt;Assuming 10 million people needing weight loss treatment and each device cost INR 200,000 that is approx $4000 the market size for weight loss&amp;nbsp; treatment is approx $40B in India alone.&lt;/b&gt; China is not too far behind.&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;object width="320" height="266" class="BLOG_video_class" id="BLOG_video-a0ccbe560341f47" classid="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"&gt;&lt;param name="movie" value="http://www.youtube.com/get_player"&gt;
&lt;param name="bgcolor" value="#FFFFFF"&gt;
&lt;param name="allowfullscreen" value="true"&gt;
&lt;param name="flashvars" value="flvurl=http://v21.nonxt6.googlevideo.com/videoplayback?id%3D0a0ccbe560341f47%26itag%3D5%26app%3Dblogger%26ip%3D0.0.0.0%26ipbits%3D0%26expire%3D1332307565%26sparams%3Did,itag,ip,ipbits,expire%26signature%3D11F04C95FABFEDC5D9BFB2F00F931B84458E4847.6FD246F77CEF3B9A55C5630AC60A4DEB878A1D40%26key%3Dck1&amp;amp;iurl=http://video.google.com/ThumbnailServer2?app%3Dblogger%26contentid%3Da0ccbe560341f47%26offsetms%3D5000%26itag%3Dw160%26sigh%3DdPMUJxB5AZRlQ27H-pedh6i2meI&amp;amp;autoplay=0&amp;amp;ps=blogger"&gt;
&lt;embed src="http://www.youtube.com/get_player" type="application/x-shockwave-flash"
width="320" height="266" bgcolor="#FFFFFF"
flashvars="flvurl=http://v21.nonxt6.googlevideo.com/videoplayback?id%3D0a0ccbe560341f47%26itag%3D5%26app%3Dblogger%26ip%3D0.0.0.0%26ipbits%3D0%26expire%3D1332307565%26sparams%3Did,itag,ip,ipbits,expire%26signature%3D11F04C95FABFEDC5D9BFB2F00F931B84458E4847.6FD246F77CEF3B9A55C5630AC60A4DEB878A1D40%26key%3Dck1&amp;iurl=http://video.google.com/ThumbnailServer2?app%3Dblogger%26contentid%3Da0ccbe560341f47%26offsetms%3D5000%26itag%3Dw160%26sigh%3DdPMUJxB5AZRlQ27H-pedh6i2meI&amp;autoplay=0&amp;ps=blogger"
allowFullScreen="true" /&gt;&lt;/object&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-177979935972079016?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/177979935972079016/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=177979935972079016' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/177979935972079016?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/177979935972079016?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/12/india-forecast-use-of-medical.html' title='India Forecast: Use of Medical Procedures Will Double by 2013'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/-x8x4QIIRsnU/TvZq5qk4J3I/AAAAAAAAAB4/17aMjniwiHQ/s72-c/BRIC1.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DUcNQH06fip7ImA9WhRXF0s.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-306286173102523694</id><published>2011-12-24T14:51:00.000-08:00</published><updated>2011-12-24T14:51:31.316-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-12-24T14:51:31.316-08:00</app:edited><title>Future of Med-Tech Sector  in BRIC Countries: 2012-2015</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;Booming med tech sector will grow at a very aggressive rate. Investments in the sector are increasing. The BRIC countries are trying to bring US innovations the countries, assuming the US regulators are posing a risk to the innovations in the US. If the innovations move to outside US. The health care cost in the US is going to dramatically increase. Yet the US VC investments&amp;nbsp; in innovative med tech sector has gone up in the 2011 and expected to increase in 2012. &amp;nbsp; &lt;br /&gt;
"Infrastructure in the BRICs has improved notably in recent years,  but still remains far behind developed country norms," according to the  report. "Infrastructure investment will need to accelerate in the years  ahead to prevent it from constraining future growth rates in the BRICs."&lt;br /&gt;
&lt;br /&gt;
&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://1.bp.blogspot.com/-h9ebPuSdJkc/TvZJahsrqwI/AAAAAAAAABg/D_SzLniSVys/s1600/BRIC.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"&gt;&lt;img border="0" src="http://1.bp.blogspot.com/-h9ebPuSdJkc/TvZJahsrqwI/AAAAAAAAABg/D_SzLniSVys/s1600/BRIC.jpg" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;br /&gt;
BRIC Countries- Individual  growth rate predictions were:&lt;br /&gt;
&lt;ul&gt;&lt;li&gt;&lt;strong&gt;Brazil&lt;/strong&gt;: 4.5 percent for 2011, 4.0 percent for 2012&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;China&lt;/strong&gt;: 9.4 percent for 2011, 9.2 percent for 2012&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;India&lt;/strong&gt;: 7.5 percent for 2011, 7.8 percent for 2012&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Russia&lt;/strong&gt;: 5.3 percent for 2011, 5.6 percent for 2012&lt;/li&gt;
&lt;/ul&gt;&lt;b&gt;RUSSIA:&lt;/b&gt; &lt;span style="font-family: Arial,Helvetica,sans-serif; font-size: small;"&gt;This is the first time that Russia has articulated a long-term &lt;a href="http://www.scribd.com/doc/40750181/Russian-Health-Care-and-the-Pharmaceutical-Industry-factsheet-via-ModernRussia-com" target="_blank"&gt;development strategy for the medical technology and pharmaceutical industries&lt;/a&gt;,  Tsyb told me. A €4.5 billion investment programme for these two sectors  was recently approved by the government, and now it is time to put that  money to good use. &lt;span id="more-25933"&gt;&lt;/span&gt;The pharmaceutical side  of the strategy is well underway; the medtech part of the programme  took a little longer to implement—a couple of signatures are required  from ministries that oversee regulatory approvals—but those are largely  pro forma, says Tsyb, and he is here in Düsseldorf to move the project  forward. His mission is to lead negotiations with international medtech  leaders interested in localisation projects within Russia as well as to  support Russian companies in their talks with potential partners.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState="false" LatentStyleCount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-parent:"";
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin:0in;
 mso-para-margin-bottom:.0001pt;
 mso-pagination:widow-orphan;
 font-size:10.0pt;
 font-family:"Times New Roman";
 mso-ansi-language:#0400;
 mso-fareast-language:#0400;
 mso-bidi-language:#0400;}
&lt;/style&gt; &lt;![endif]--&gt;&lt;span style="font-size: 12pt;"&gt;&lt;span style="font-size: small;"&gt;The market, which is currently valued at €3.5 billion, is projected to grow six-fold by 2020, according to government forecasts.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: 12pt;"&gt;&lt;span style="font-size: small;"&gt;&lt;b&gt;CHINA:&lt;/b&gt; &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;/strong&gt;&lt;span style="font-family: Arial,Helvetica,sans-serif; font-size: small;"&gt;The government’s 4 trillion RMB stimulus package and  policies to boost domestic demand have helped most Chinese companies,  but the medical device industry has benefited less than other  industries. Because most SMEs manufacture only for the domestic market  and medical device demand is determined by domestic institutions, recent  medical reforms have not done a great deal to stimulate demand. Some  export-oriented companies rely on OEM services and do not benefit from  the expansion of domestic demand. If companies can think outside the box  and try to expand foreign demand for their products, this might be a  way to achieve quick economic gains. The financial crisis has decreased  demand for traditional exports, but the decrease in purchasing power of  foreign healthcare systems has also decreased the competitiveness of  many foreign medical device SMEs. This gives Chinese companies a good  opportunity to take advantage of their low manufacturing costs to get a  foothold in foreign markets. &lt;/span&gt; &lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt; For years, companies have been succeeding in the domestic market but  have not tried to expand overseas. This can be attributed, in part, to  language and cultural barriers and to unfamiliarity with foreign market  regulations. In the European Union, Chinese medical device companies  only need to obtain CE certification to be eligible to directly enter  more than 20 member states. CE certification is much less stringent than  SFDA certification. Some small pharmaceutical companies have obtained  CE certification while waiting for SFDA certification and marketed their  products overseas right away. I suspect such strategies will become  more and more popular. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;  &lt;span style="font-size: small;"&gt;&lt;strong&gt;Use human resources to accelerate the pace of product commercialization.&lt;/strong&gt;   Medical device development in China lacks the support of national  research institutions, which are often out of sync with practical needs.  This leaves technology and product development in the hands of medical  device companies. Unfortunately most medical device companies use their  limited investment funds to expand production and sales rather than to  develop new products or technologies. China’s so-called new products are  often imitations of foreign products, which limit the impact they might  have on foreign markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;  Medical devices, especially small products, can be developed and  manufactured in a relatively short time-frame, and human resources can be  harnessed to drive innovation. Over the past 30 years of opening and  reform, a significant portion of the 200,000+ Chinese students who have  studied abroad have gone to work for major medical device manufactures.  Domestic companies should find ways to put these intangible assets and  technological assets to use.&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;b&gt;&lt;span style="font-size: small;"&gt;BRAZIL: &lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Myriad Pro; font-size: small;"&gt;Brazil has the largest economy and &lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;a href="http://www.espicom.com/ProdCat2.nsf/Product_Alt_URL_Lookup/medical_devices_latin_america?OpenDocument" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;u&gt;&lt;span style="color: #c80c00;"&gt;medical device market in Latin America&lt;/span&gt;&lt;/u&gt;&lt;/a&gt;&lt;/span&gt;&lt;span style="font-family: Myriad Pro; font-size: small;"&gt;,  but per capita medical expenditure is still very low. The market fell  in 2009 but recovered in 2010. The highest expenditure is in the large  cities, such as Sao Paulo or Rio de Janeiro, but producers are moving  into regional markets outside the major state capitals. Diagnostic  imaging apparatus, followed by obesity weight loss, diabetes, orthopaedics, spine and consumables are the  largest market sectors. &lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;br style="font-family: Arial,Helvetica,sans-serif;" /&gt;&lt;/span&gt;  &lt;span style="font-family: Myriad Pro; font-size: small;"&gt;Dilma Roussef took office as President on January 1&lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;sup style="font-family: Arial,Helvetica,sans-serif;"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family: Myriad Pro; font-size: small;"&gt; 2011, she has not decided whether herself or her predecessor Lula will run for the next elections in 2014. &lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;br style="font-family: Arial,Helvetica,sans-serif;" /&gt;&lt;/span&gt;  &lt;span style="font-family: Myriad Pro; font-size: small;"&gt;Brazil, and Latin America in general, have  emerged more quickly from the global downturn than more developed  nations. Additionally the region is projected to grow at a faster rate  in the near future. Brazil’s GDP is set to expand by a healthy 4.3% in  2011 and growth will be between 4% and 5% over the medium term. With a  growing economy, if inflation is kept in check,&lt;b&gt; there will be more money  available to spend on healthcare both in the public and private  sectors.&lt;/b&gt;&lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;br style="font-family: Arial,Helvetica,sans-serif;" /&gt;&lt;/span&gt;  &lt;span style="font-family: Myriad Pro; font-size: small;"&gt;The shape of the medical device and diagnostic imaging sector is  expected to change following recently announced manufacturing  investments. In June 2010, GE Healthcare opened its first South American  plant in Brazil, focusing around “healthymagination”. The factory  represents an investment of US$50 million over 10 years. Philips  Healthcare inaugurated the first Latin American plant for the production  of MRI equipment in Brazil in October 2008. &lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;br style="font-family: Arial,Helvetica,sans-serif;" /&gt;&lt;/span&gt;  &lt;span style="font-family: Myriad Pro; font-size: small;"&gt;Imports hold a relatively small share of the  market, totalling US$1.8 billion in 2009. The economic slowdown and a  more “realistic” exchange rate in 2009 have contained medical imports as  imports increased just 1.7% in 2009 compared to a CAGR 2005-09 of  21.1%. Imports tend to be high-tech medical equipment not produced  locally. In 2009, 68% of imports were supplied by Europe and the USA. &lt;/span&gt;&lt;span style="font-size: small;"&gt;&lt;br style="font-family: Arial,Helvetica,sans-serif;" /&gt;&lt;/span&gt;  &lt;span style="font-family: Myriad Pro; font-size: small;"&gt;Medical exports reached US$442.3 million in  2009, reflecting a less favourable exchange rate. The country has a  well-established medical industry, comprising local and multinational  companies. Domestic production, however, is geared towards the local  market. Exports are small in comparison with total production and the  country consistently runs a negative balance of trade in medical  equipment and supplies&lt;/span&gt;&lt;span style="font-family: Arial,Helvetica,sans-serif; font-size: small;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;b&gt;&lt;span style="font-size: small;"&gt;&lt;span style="font-size: 12pt;"&gt;INDIA: &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;India’s medical device and equipment market is expected to reach US$6.41  million by 2014, growing 15.5% annually. The market has opened up for  importers, MNCs as well as indigenous manufacturers. Driving this growth  is increased awareness and affordability coupled with an expanding  patient pool and ever-growing export demands from Western and emerging  markets. The Indian medical device market is booming, writes emerging markets according to Sonali Deshpande of TrialMed Life Sciences in India. Currently valued at approximately US$3 billion, &lt;a href="http://www.qmed.com/consultants/india-medical-device-market-updates" target="_blank"&gt;India’s medtech market&lt;/a&gt; is expected to grow 12% to 16% during the next five years (2016) &lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-306286173102523694?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/306286173102523694/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=306286173102523694' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/306286173102523694?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/306286173102523694?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/12/future-of-med-tech-sector-in-bric.html' title='Future of Med-Tech Sector  in BRIC Countries: 2012-2015'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/-h9ebPuSdJkc/TvZJahsrqwI/AAAAAAAAABg/D_SzLniSVys/s72-c/BRIC.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;C0cARnw6fip7ImA9WhRXF0s.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-5467058898346755059</id><published>2011-12-24T13:10:00.000-08:00</published><updated>2011-12-24T13:10:47.216-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-12-24T13:10:47.216-08:00</app:edited><title>Canadian Med Tech Sector Hot 2012-2015</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;div class="MsoNormal"&gt;&lt;b&gt;&lt;span style="font-size: 18pt;"&gt;Canadian Med Tech Sector Hot 2012-2015 &lt;/span&gt;&lt;/b&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;The health care industry in Canada has experienced steady growth in the past decade, driven by universal access to health care, an aging population, rise of lifestyle disease rates, and advances in the pharmaceutical and medical technologies. Key challenges facing the Canadian health care sector include extended wait times leading to limited access to services and a rising health care financing deficit. Part of the complex solution for solving both challenges includes the adoption of advanced medical technologies, which can have a long term result of lower per-treatment cost and duration, as well as better health outcomes.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;  &lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;The outlook for medical technology sector looks very bullish. The med tech sector is trending the same way as the Israel, Ireland, China, India, Brazil and US medtech sectors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;US&lt;/span&gt;&lt;span class="A0"&gt; med tech sector is going to be in demand as innovation is all time high across the sectors. The impact of obesity and obesity related problems has created new opportunities in the weight loss, cardiovascular, spine and orthopedic market.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;Also, following the US regulatory system may do more harm to the Canadian med tech sector. Following the EU system is the most ideal system.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;The United   States remains overwhelmingly the primary market for Canadian medical device exports and the destination for approximately 71% of al&lt;/span&gt;&lt;span class="A0"&gt;l medical device exports in 2010&lt;/span&gt;&lt;span class="A0"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt;Many of the large international medical device manufacturers are represented in the market, though relatively few have set up manufacturing plants locally, preferring to maintain only their sales team in Canada. The Canadian medical device mark&lt;/span&gt;&lt;span class="A0"&gt;et is estimated at $6 B in 2010&lt;/span&gt;&lt;span class="A0"&gt;, is primarily an import market; with 52% of all imports destined for the US.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;span style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt;"&gt;&lt;/span&gt;&lt;br /&gt;
&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;span style="font-size: small;"&gt;&lt;span class="A0"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://4.bp.blogspot.com/-FkSLVX2VUb4/TvY6gQScRpI/AAAAAAAAAAc/DhK368R1Ufw/s1600/Canada1.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="392" src="http://4.bp.blogspot.com/-FkSLVX2VUb4/TvY6gQScRpI/AAAAAAAAAAc/DhK368R1Ufw/s640/Canada1.jpg" width="640" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="separator" style="clear: both; text-align: center;"&gt;&lt;a href="http://1.bp.blogspot.com/-3wRGS23MYQg/TvY68o_uviI/AAAAAAAAAAo/wIGv8obmKBs/s1600/canada+2.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"&gt;&lt;img border="0" height="494" src="http://1.bp.blogspot.com/-3wRGS23MYQg/TvY68o_uviI/AAAAAAAAAAo/wIGv8obmKBs/s640/canada+2.jpg" width="640" /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="font-family: Arial,Helvetica,sans-serif;"&gt;&lt;br /&gt;
&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-5467058898346755059?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/5467058898346755059/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=5467058898346755059' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5467058898346755059?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5467058898346755059?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/12/canadian-med-tech-sector-hot-2012-2015.html' title='Canadian Med Tech Sector Hot 2012-2015'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/-FkSLVX2VUb4/TvY6gQScRpI/AAAAAAAAAAc/DhK368R1Ufw/s72-c/Canada1.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;C0EBRn05fSp7ImA9WhRQEk4.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8067484489303515263</id><published>2011-12-06T20:20:00.001-08:00</published><updated>2011-12-06T20:20:57.325-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-12-06T20:20:57.325-08:00</app:edited><title>“Growth in the life sciences industries will greatly depend on how the FDA responds to growing complaints that they are stifling medical technologies.  Companies have seen a vast difference in the approval processes in Europe vs. the U.S</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;div dir="ltr" style="text-align: left;"&gt;&lt;em&gt;By: The  Advanced Medical Technology Association (“AdvaMed”),  prepared by Josh  Makower, M.D., consulting Professor of Medicine,  Stanford University&amp;nbsp;&lt;/em&gt;&lt;br /&gt;
A medical device meeting recently reported that “Growth in the life  sciences  industries will greatly depend on how the FDA responds to  growing  complaints that they are stifling medical technologies.&amp;nbsp;  Companies have  seen a vast difference in the approval processes in  Europe vs. the U.S.&amp;nbsp;  A study released by Stanford University indicated  that the cost of  bringing a technology to market is dramatically lower  in Europe.”&lt;br /&gt;
The Advanced Medical Technology Association (“AdvaMed”) recently   released the report, prepared by Josh Makower, M.D., consulting   Professor of Medicine, Stanford University and Founder, President &amp;amp;   Chief Executive Officer of ExploraMed Development, LLC; et al, “FDA   Impact on U.S. Medical Technology Innovation,” which garnered responses   from more than 200 companies concerning their experiences in working   with the FDA.&amp;nbsp; Participants were also asked about their experiences   working with European regulatory authorities in order to offer a   comparison between aspects of the two dominant regulatory systems.&lt;br /&gt;
“In general, survey respondents viewed current U.S. regulatory   processes for making products available to patients as unpredictable and   characterized by disruptions and delays,” the results summary states.&amp;nbsp;   Forty-four percent (44%) indicated that part way through the premarket   regulatory process they experienced untimely changes in key personnel,   including the lead reviewer and/or branch chief responsible for the   product’s evaluation.&amp;nbsp; Thirty-four percent (34%) of respondents also   reported that appropriate FDA staff and/or physician advisors to the FDA   were not present at key meetings between the FDA and the company.”&lt;br /&gt;
The report goes on to highlight that those factors contribute to   significant delays in navigating FDA regulatory processes, with   premarket process for 510(k) pathway devices (of low-to moderate risk)   taking an average of 10 months from first filing to clearance.&amp;nbsp; Devices   requiring a clinical study for low- to moderate-risk devices before   making a regulatory submission, the premarket process took an average of   31 months from first communication to being cleared to market while,  in  comparison, it took an average of 7 months in Europe.&lt;br /&gt;
For higher risk devices seeking premarket approvals, responding   companies indicated that it took an average of 54 months to work with   the FDA from first communication to being approved to market the   device.&amp;nbsp; In Europe, it took an average of 11 months.”&lt;br /&gt;
Beyond the time gap comparing FDA and Europe approval processes, the   survey also showed that the average total cost for a low- to   moderate-risk 510(k) product from concept to clearance was approximately   $31 million, with $24 million spent on FDA dependent and/or related   activities.&amp;nbsp; For a higher-risk PMA product, the average total cost from   concept to approval was approximately $94 million, with $75 million   spent on stages linked to the FDA.&lt;br /&gt;
According to the report, these statistics result in a “significant,   measurable cost to U.S. patients in the form of a device lag.&amp;nbsp;   Respondents reported that their devices were available to U.S. citizens,   on average, nearly 2 full years later than patients in other  countries,  due to delays with the FDA and/or company decisions to  pursue markets  outside the U.S. before initiating time-consuming,  expensive regulatory  processes in their own country.”&lt;br /&gt;
&lt;em&gt;&lt;br /&gt;
&lt;/em&gt;Stephen J. Ubl, President &amp;amp; Chief Executive Officer of AdvaMed,   says, “This report is a wake-up call for those who want to promote   medical innovation and preserve American jobs.&amp;nbsp; A regulatory environment   that is marked by needless delays and inefficiencies makes it harder   for medical innovation to thrive and companies to survive.&amp;nbsp; These delays   particularly hurt small companies and their ability to produce next   generation technologies.”&lt;em&gt;&lt;/em&gt;&lt;br /&gt;
&lt;em&gt;To read the full report go to: &lt;a href="http://www.advamed.org/NR/rdonlyres/040E6C33-380B-4F6B-AB58-9AB1C0A7A3CF/0/makowerreportfinal.pdf"&gt;http://www.advamed.org/NR/rdonlyres/040E6C33-380B-4F6B-AB58-9AB1C0A7A3CF/0/makowerreportfinal.pdf&lt;/a&gt;&lt;/em&gt;&lt;br /&gt;
&lt;em&gt;&lt;/em&gt;Ultimately, growth within the life sciences will continue at  a  quick pace during the next few years, with development of R&amp;amp;D   pipelines, alliances, and partnerships being a key factor for success.&lt;br /&gt;
As the economy continues to chug back to full force, the only  obstacle  appears to be the differing of opinions between the medical  device  manufacturers and the FDA.&amp;nbsp; Perhaps if they come to a meeting of  the  minds, these growth projections will not just be projections, but  will  be the reality of a growing field that is quickly, and effectively,   delivering what the U.S. healthcare system requires.”&lt;em&gt;&lt;br /&gt;
&lt;/em&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8067484489303515263?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8067484489303515263/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8067484489303515263' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8067484489303515263?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8067484489303515263?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/12/growth-in-life-sciences-industries-will.html' title='“Growth in the life sciences industries will greatly depend on how the FDA responds to growing complaints that they are stifling medical technologies.  Companies have seen a vast difference in the approval processes in Europe vs. the U.S'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;Ck8GSHk8fSp7ImA9WhRXF0s.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-5308399620853691650</id><published>2011-12-06T20:19:00.001-08:00</published><updated>2011-12-24T13:07:09.775-08:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-12-24T13:07:09.775-08:00</app:edited><title>“FDA Impact on U.S. Medical Technology Innovation,”</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;“FDA  Impact on U.S. Medical Technology Innovation,”&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-5308399620853691650?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/5308399620853691650/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=5308399620853691650' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5308399620853691650?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/5308399620853691650?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/12/fda-impact-on-us-medical-technology.html' title='“FDA Impact on U.S. Medical Technology Innovation,”'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;D0YDR38yeyp7ImA9WhdWFkU.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8932176435027580849</id><published>2011-09-10T13:06:00.000-07:00</published><updated>2011-09-10T13:06:16.193-07:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-09-10T13:06:16.193-07:00</app:edited><title>Obesity Devices And The FDA Review Process: Enormous &amp; Unmet Need</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;h3 class="yiv1072868720entry-header"&gt;Obesity Devices And The FDA Review Process: An Interview With Lee Kaplan, MD&lt;/h3&gt;&lt;div&gt;With increasing concerns about the US Food &amp;amp; Drug Administration  (FDA) review process and its impact on innovation in the obesity arena,  members of academia and industry are working with the FDA to identify  best practices for clinical trials and help standardize the clinical  investigation and review process. As part of this initiative, the FDA, &lt;a href="http://sis.windhover.com/document.php?id=198800653" rel="nofollow" target="_blank"&gt;&lt;strong&gt;Massachusetts General Hospital&lt;/strong&gt;&lt;/a&gt; (MGH), and &lt;a href="http://companies.windhover.com/Content/Company.aspx?CoId=198700792&amp;amp;utm_source=mdt" rel="nofollow" target="_blank"&gt;&lt;strong&gt;Dartmouth College&lt;/strong&gt;&lt;/a&gt;  are sponsoring a much anticipated public meeting and workshop in  October 2011 that will focus on delineating best practices for clinical  trials in the field of bariatrics. To find out more, &lt;em&gt;Medtech Insight&lt;/em&gt;  interviewed one of the meeting co-directors, Lee Kaplan, MD, director  of the Obesity, Metabolism and Nutrition Institute at MGH, in Boston.  According to Kaplan, patient need in the obesity field is &lt;span style="font-style: italic; font-weight: bold;"&gt;"enormous and  generally unmet,"&lt;/span&gt; so it is important for the field to "adopt strategies  that will facilitate bringing new, effective therapies to market."&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Q:&lt;/strong&gt; &lt;em&gt;Medtech Insight:&lt;/em&gt; How has academia been working with the FDA in terms of improving the FDA review process for weight loss devices?&lt;/div&gt;&lt;div id="yui_3_2_0_1_1315637324528194"&gt;&lt;em&gt;Lee Kaplan:&lt;/em&gt; We've been working with the FDA to help identify  best practices for clinical trials of devices for obesity and metabolic  disorders and how to assess the effectiveness of medical devices in  this area in a more standardized and predictable way. It has been a  stepwise process. Because of the importance of this effort,  representatives of the American Society for Metabolic and Bariatric  Surgery (ASMBS) and the American Society for Gastrointestinal Endoscopy  (ASGE) met with the FDA in the summer of 2010 and recently presented a  white paper outlining the perspective of these two societies regarding  what should be done in this area. &lt;span style="font-weight: bold;"&gt;In follow-up to that, we are putting  together a public meeting in October, sponsored by the FDA, MGH, and  Dartmouth, to take it to the next level. The meeting will be a workshop  on clinical trials and GI devices for the treatment of obesity and  related metabolic disorders. The conference is being formulated right  now, and over the next couple of weeks we will distribute the details.&lt;/span&gt;&lt;/div&gt;&lt;h3 class="yiv1072868720entry-header"&gt;&amp;nbsp;&lt;/h3&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8932176435027580849?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8932176435027580849/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8932176435027580849' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8932176435027580849?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8932176435027580849?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/09/obesity-devices-and-fda-review-process.html' title='Obesity Devices And The FDA Review Process: Enormous &amp; Unmet Need'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;DkAFRHY5cCp7ImA9WhdWFkU.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-1138584544866429002</id><published>2011-09-10T12:58:00.000-07:00</published><updated>2011-09-10T12:58:35.828-07:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-09-10T12:58:35.828-07:00</app:edited><title>Life sciences dollars jump 37% from first quarter 2011 Internet-specific investments at 10-year high level</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;Venture capitalists invested $7.5 billion in 966 deals in the second  quarter of 2011, investment activity increased 19 percent in terms of  both dollars and the number of deals compared to the first quarter of  2011 when $6.3 billion was invested in 814 deals.&lt;br /&gt;
&lt;br /&gt;
The Life Sciences sector (biotechnology and medical device industries  combined) saw an increase in VC dollars invested during the second  quarter, rising 37 percent in dollars and 12 percent in deal volume from  the prior quarter to $2.1 billion going into 206 deals.  Investments in  Internet-specific companies also rose considerably to the highest  quarterly level since 2001.&lt;br /&gt;
&lt;br /&gt;
"The rise in venture capital investments going into the Life Sciences  and Internet sectors can be attributed to the increase in exit activity  in the Life Sciences sector and attractive valuations for Internet  companies," noted Tracy T. Lefteroff, global managing partner of the  venture capital practice at PwC US.  "The exit market for both biotech  and medical device companies has been active over the past year, and  this has encouraged VCs to put more money back to work in this space.  &lt;br /&gt;
At the current pace of venture capital investing, 2011 is on track to  exceed $26 billion, which would put it as the sixth most active year in  VC investing history."&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-1138584544866429002?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/1138584544866429002/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=1138584544866429002' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1138584544866429002?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1138584544866429002?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/09/life-sciences-dollars-jump-37-from.html' title='Life sciences dollars jump 37% from first quarter 2011 Internet-specific investments at 10-year high level'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;C0YNQH46eip7ImA9WhdQGU0.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-1772007811152818415</id><published>2011-08-20T21:29:00.000-07:00</published><updated>2011-08-20T21:33:11.012-07:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-08-20T21:33:11.012-07:00</app:edited><title>India has largest pool of patients for clinical trials</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:browserlevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate="false" latentstylecount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if !mso]&gt;&lt;object classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id="ieooui"&gt;&lt;/object&gt; &lt;style&gt; st1\:*{behavior:url(#ieooui) } &lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0in 5.4pt 0in 5.4pt; 	mso-para-margin:0in; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} &lt;/style&gt; &lt;![endif]--&gt;    &lt;p&gt;By: Trialmed editor&lt;/p&gt;  &lt;p&gt;Aug 20, 2011&lt;/p&gt;  &lt;p&gt;India these days has the largest pool of patients suffering from cancer, obesity, diabetes and metabolic syndrome is leading the country to an altogether different destination: the global hub of outsourcing of clinical trials. India with its booming economy has both the diseases of the west and the diseases of the east.&lt;/p&gt;  &lt;p&gt;Almost all the top names in the pharmaceutical world have zeroed-in on India, setting up clinical trail facilities in major cities, especially Pune, Mumbai, Hydearbad and Ahmedabad and Bangalore. This is because India offers western trained doctors and english  speaking patients for the most parts in the above mentioned cities.&lt;br /&gt;&lt;/p&gt;  &lt;p&gt;Global consultancy McKinsey &amp;amp; Co estimated that by 2011, global pharma majors would spend around $1-1.5 billion just for drug trials in the country.&lt;/p&gt;  &lt;p&gt;Data from the US government’s global trials registry, clinicaltrial.gov, show only 246 clinical trials were held in India in 2009. That was 9.6 per cent lower than the number of trials a year before. On the other hand, the number in China (316) and Korea (397) grew 15.3 per cent and 20.7 per cent, respectively, in 2009 as against the previous year. &lt;/p&gt;  &lt;p&gt;If India has the patient population, as much of Latin America and EU combined. Why have the number of clinical trials dipped. The answer is the time lag in the regulatory approvals, once an easy approval process has become extremely bureaucratic process, by the time the study is approved, the investigators have lost interest in the study.&lt;/p&gt;  &lt;p&gt;Investigators who are mostly key opinion leaders have very little time to follow the process laid out by the protocol, leading to protocol deviations and paucity of time to complete the documents. &lt;/p&gt;  &lt;p&gt;CROs have played a big role in combating the above problems, but in doing so the competitive pricing is not available.&lt;/p&gt;  &lt;p&gt;We still believe that the smaller CROs have more potential and time to offer to companies that can spend the time to work with the approval process, training of the doctors and the CRA with the protocol and study requirements. Helping CROs develop study information packets enables patient recruitment per protocol and keeps the enthusiasm of the study high. &lt;/p&gt;  &lt;p&gt;CROs like TrialMed India &lt;a href="http://www.trialmed.com/"&gt;www.trialmed.com&lt;/a&gt; are providing clinical trial support and marketing support to the early start ups who want to do clinical trials in India. They are also available for large medical device firms to market their medical devices in India.&lt;/p&gt;  &lt;p&gt; &lt;/p&gt;  &lt;p class="MsoNormal"&gt; &lt;/p&gt;  &lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-1772007811152818415?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/1772007811152818415/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=1772007811152818415' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1772007811152818415?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/1772007811152818415?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/08/india-has-largest-pool-of-patients-for.html' title='India has largest pool of patients for clinical trials'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry gd:etag='W/&quot;A0UMSXk_cCp7ImA9WhdQGEQ.&quot;'><id>tag:blogger.com,1999:blog-4821206398479924898.post-8988747460881995497</id><published>2011-08-20T21:00:00.000-07:00</published><updated>2011-08-20T21:01:28.748-07:00</updated><app:edited xmlns:app='http://www.w3.org/2007/app'>2011-08-20T21:01:28.748-07:00</app:edited><title>FDA to relax regulations</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;   &lt;/w:Compatibility&gt;   &lt;w:browserlevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;  &lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate="false" latentstylecount="156"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0in 5.4pt 0in 5.4pt; 	mso-para-margin:0in; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} &lt;/style&gt; &lt;![endif]--&gt;  &lt;p&gt;&lt;span style="font-family: Arial;"&gt;By: Trialmed editor&lt;/span&gt;&lt;/p&gt;  &lt;p&gt;&lt;span style="font-family: Arial;"&gt;Aug 19, 2011&lt;/span&gt;&lt;/p&gt;  &lt;p&gt;&lt;span style="font-family: Arial;"&gt;&lt;a href="http://www.mdci.com/services/" target="_blank"&gt;&lt;span style="color: windowtext; text-decoration: none;"&gt;Medical device companies&lt;/span&gt;&lt;/a&gt; operating in the &lt;em&gt;&lt;span style="font-family: Arial;"&gt;in vitro&lt;/span&gt;&lt;/em&gt; diagnostic and radiology sectors of the industry received some surprising news this past month when it was revealed that the FDA had decided to relax certain regulatory requirements pertaining to these products.  Specifically, &lt;a href="http://www.fiercemedicaldevices.com/press-releases/fda-proposes-new-policy-some-diagnostic-and-radiology-devices-0"&gt;&lt;span style="color: windowtext; text-decoration: none;"&gt;a number of device types will now be exempt from pre- market notification requirements&lt;/span&gt;&lt;/a&gt;. The FDA move, which affects approximately 30 medical device types ranging from radiology film processors to blood testing, was prompted by the long track record of safety and effectiveness of each respective product.  CDRH Director Jeffrey Shuren stated that &lt;i style=""&gt;“the agency is taking a smart regulatory approach that eases unnecessary requirements for manufacturers,”&lt;/i&gt; without risking the health of the public in the process.  The FDA has also stated that this is the first step in what will be a gradual loosening of &lt;a href="http://www.mdci.com/services/regulatory/510k-submission.php"&gt;&lt;span style="color: windowtext; text-decoration: none;"&gt;510(k) requirements&lt;/span&gt;&lt;/a&gt; across the board for low-risk radiology and &lt;em&gt;&lt;span style="font-family: Arial;"&gt;in vitro&lt;/span&gt;&lt;/em&gt; diagnostic devices. Until this occurs, the FDA will exercise what it calls “enforcement discretion” in handling pre-market notification submissions for the 30 medical device types described within the document.  There is as of yet no timetable for the adoption of this dramatic shift in medical device regulatory approval standards, but a 90-day comment period on the proposal is currently in effect.&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"&gt; &lt;/p&gt;  &lt;div class="blogger-post-footer"&gt;Join Scientific Entrepreneur &amp; Venture Capital Network on Linkedin&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4821206398479924898-8988747460881995497?l=devicetrialsindia.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://devicetrialsindia.blogspot.com/feeds/8988747460881995497/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4821206398479924898&amp;postID=8988747460881995497' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8988747460881995497?v=2'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4821206398479924898/posts/default/8988747460881995497?v=2'/><link rel='alternate' type='text/html' href='http://devicetrialsindia.blogspot.com/2011/08/fda-to-relax-regulations.html' title='FDA to relax regulations'/><author><name>Raj Nihalani, M.D., RAC(US)</name><uri>http://www.blogger.com/profile/02763516364988911055</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>